Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Neoplasms of the CNS

Free Subscription Articles published in Neuro Oncol Retrieve available abstracts of 578 articles: HTML format

Single Articles

September 2025
1. SUSSMAN JH, Cillo AR, Kohli S, Cardello C, et al
   Single-cell profiling of peripheral and local immune compartments reveal unique genotype-independent prognostic immune signatures across IDH-stratified glioma.
   Neuro Oncol. 2025 Sep 20:noaf206. doi: 10.1093.
   PubMed     Abstract available
   
   
   
2. ZHANG J, Chen X, Cheng M, Wang J, et al
   Multiple patient-derived glioblastoma models reveal synthetic lethality through concurrent PI3K and CDK4/6 inhibition by blocking trans-active cooperation.
   Neuro Oncol. 2025 Sep 18:noaf224. doi: 10.1093.
   PubMed     Abstract available
   
   
   
3. SUAREZ-MEADE P, Whitehead R, Rosenfeld S, Schiapparelli P, et al
   Extracellular Matrix Stiffness Conditions Glioblastoma Cells for Long-term Migration: Mechanical Memory as a Driver of Invasion and Recurrence in Glioblastoma.
   Neuro Oncol. 2025 Sep 17:noaf205. doi: 10.1093.
   PubMed     Abstract available
   
   
   
4. GOLDBRUNNER R, Foroglou N, Signorelli F, Schucht P, et al
   EANS-EANO Guidelines on the extent of resection in gliomas.
   Neuro Oncol. 2025 Sep 17:noaf217. doi: 10.1093.
   PubMed     Abstract available
   
   
   
5. DEACON S, Cahyani I, Holmes N, Fox G, et al
   ROBIN: A unified nanopore-based assay integrating intraoperative methylome classification and next-day comprehensive profiling for ultra-rapid tumor diagnosis.
   Neuro Oncol. 2025;27:2035-2046.
   PubMed     Abstract available
   
   
   
6. SCHAFF LR, Piotrowski AF, Pentsova E, Gavrilovic IT, et al
   Phase Ib study with expansion of ibrutinib, lenalidomide, and rituximab in patients with relapsed/refractory central nervous system lymphoma.
   Neuro Oncol. 2025;27:2107-2116.
   PubMed     Abstract available
   
   
   
7. FALTINGS LJ, Lin F, Zahran M, Jalili H, et al
   SOX2 commands LIM homeobox transcription factors in choroid plexus development and tumorigenesis.
   Neuro Oncol. 2025;27:2006-2022.
   PubMed     Abstract available
   
   
   
8. GUST J, Cole BL, Ronsley R, Wilson AL, et al
   Locoregional infusion of EGFR806-CAR T cells for recurrent or refractory pediatric CNS tumors: Results of the completed BrainChild02 phase 1 clinical trial.
   Neuro Oncol. 2025;27:2170-2181.
   PubMed     Abstract available
   
   
   
9. HERNANDEZ-VERDIN I, Kirasic E, Mokhtari K, Barillot N, et al
   Gut microbiome modulates the outcome in primary central nervous system lymphoma patients undergoing chemotherapy: An ancillary study from the BLOCAGE trial.
   Neuro Oncol. 2025;27:2090-2104.
   PubMed     Abstract available
   
   
   
10. FIORANTE A, Woolman M, Munoz DG, Kiyota T, et al
    A molecular array for 10-second diagnosis of common spinal tumor types with picosecond infrared laser mass spectrometry.
    Neuro Oncol. 2025;27:2060-2072.
    PubMed     Abstract available
    
    
    
11. HOU N, Wang Y, You Q, Zhang L, et al
    EGFR/ZBED1 reciprocal regulation promotes stemness and tumorigenesis in glioblastoma.
    Neuro Oncol. 2025 Sep 15:noaf215. doi: 10.1093.
    PubMed     Abstract available
    
    
    
12. XIE H, Ji T, Zhang C, Cheng M, et al
    Co-activation of super-enhancer complex SOX2 and HDAC1 confers temozolomide resistance by promoting PDGFB transcription in glioblastoma.
    Neuro Oncol. 2025 Sep 15:noaf219. doi: 10.1093.
    PubMed     Abstract available
    
    
    
13. 
    PBTF Childhood and Adolescent Brain Tumor Facts.
    Neuro Oncol. 2025;27.
    PubMed    
    
    
    
14. PRICE M, Ballard CAP, Benedetti JR, Kruchko C, et al
    CBTRUS Statistical Report: Pediatric Brain Tumor Foundation Childhood and Adolescent Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2017-2021.
    Neuro Oncol. 2025;27.
    PubMed     Abstract available
    
    
    
15. SISKAR AN, Hanzlik E, Cardenas MF, Eldomery MK, et al
    FOXR2 activation is not exclusive of CNS neuroblastoma.
    Neuro Oncol. 2025;27:1801-1812.
    PubMed     Abstract available
    
    
    
16. KRANENDONK MEG, Hoogendijk R, Lammers JAS, van der Lugt J, et al
    Do we need B7-H3 immunohistochemistry for the inclusion of children with high-grade central nervous system tumors in clinical trials targeting B7-H3?
    Neuro Oncol. 2025;27:1864-1877.
    PubMed     Abstract available
    
    
    
17. KLAASSEN D, Mok S, Hwang JY, Blount SL, et al
    Postoperative fluid restriction to prevent delayed hyponatremia after endoscopic transsphenoidal surgery.
    Neuro Oncol. 2025;27:1746-1757.
    PubMed     Abstract available
    
    
    
18. UPTON DH, Liu J, George SM, Valvi S, et al
    High-throughput in vitro drug screening and in vivo studies identify fenretinide as a brain-penetrant DMG therapeutic.
    Neuro Oncol. 2025;27:1813-1828.
    PubMed     Abstract available
    
    
    
19. OH JH, Reed SK, Riviere-Cazaux C, Kim M, et al
    Window of opportunity evaluation of blood-brain barrier permeability heterogeneity within and across high-grade glioma patients.
    Neuro Oncol. 2025 Sep 6:noaf204. doi: 10.1093.
    PubMed     Abstract available
    
    
    
20. HADDAD AF, Ramesh R, Zakimi N, Chen JS, et al
    Preoperative embolization improves local control and modulates gene expression in atypical WHO grade 2 meningioma.
    Neuro Oncol. 2025 Sep 2:noaf203. doi: 10.1093.
    PubMed     Abstract available
    
    
    
21. AJAIB S, Winter-Luke J, Digby RJ, Pollock S, et al
    Spatial profiling of longitudinal glioblastoma reveals consistent changes in cellular architecture, post-treatment.
    Neuro Oncol. 2025 Sep 1:noaf190. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2025
22. BETTEGOWDA C, Noushmehr H, Affinito A, Ahluwalia MS, et al
    Preanalytical variables and analytes in liquid biopsy approach for brain tumors: A comprehensive review and recommendations from the RANO Group and the Brain Liquid Biopsy Consortium.
    Neuro Oncol. 2025 Aug 30:noaf140. doi: 10.1093.
    PubMed     Abstract available
    
    
    
23. CHOI WS, Jeon P, Peyton S, Garg M, et al
    Glioblastoma Tumor Microtubes and Brain Fatty Acid-binding Protein: Path to Directional Infiltration.
    Neuro Oncol. 2025 Aug 28:noaf200. doi: 10.1093.
    PubMed     Abstract available
    
    
    
24. GUI C, Walch HS, Mueller KD, Boe LA, et al
    Genomics correlates of brain metastasis and progression in colorectal cancer.
    Neuro Oncol. 2025 Aug 28:noaf198. doi: 10.1093.
    PubMed     Abstract available
    
    
    
25. INNANI S, Bell WR, Nasrallah MP, Baheti B, et al
    AI-driven WHO 2021 classification of gliomas based only on H&E-stained slides.
    Neuro Oncol. 2025 Aug 28:noaf189. doi: 10.1093.
    PubMed     Abstract available
    
    
    
26. CHO NS, Le VL, Teraishi A, Liu V, et al
    Perfusion, diffusion, and anatomical MRI characteristics of pathologically-confirmed malignant transformation in IDH-mutant gliomas.
    Neuro Oncol. 2025 Aug 28:noaf171. doi: 10.1093.
    PubMed     Abstract available
    
    
    
27. GORTER M, Rottgering JG, Belgers V, van Lingen MR, et al
    Distinct and Reproducible Neurocognitive Profiles in Stable Diffuse Glioma: A Data-Driven Approach to Understanding Cognitive Heterogeneity.
    Neuro Oncol. 2025 Aug 27:noaf197. doi: 10.1093.
    PubMed     Abstract available
    
    
    
28. WU BX, Kreatsoulas D, Cam H, Bolyard C, et al
    Targeting TGFbeta docking receptor Glycoprotein A Repetitions Predominant (GARP) via novel chimeric antigen receptor (CAR)-T cell platform to treat glioblastoma.
    Neuro Oncol. 2025 Aug 27:noaf195. doi: 10.1093.
    PubMed     Abstract available
    
    
    
29. LEELATIAN N, Singh C, Bouffard R, Sundaram RK, et al
    DNA damage response profile distinguishes poor-acting gliomas with shared methylome signatures.
    Neuro Oncol. 2025 Aug 27:noaf199. doi: 10.1093.
    PubMed     Abstract available
    
    
    
30. MAEDA S, Kitano Y, Ohka F, Motomura K, et al
    Rapid Intraoperative Genetic Analysis of Adult-type Diffuse Gliomas Using a Microfluidic Real-Time Polymerase Chain Reaction Device.
    Neuro Oncol. 2025 Aug 24:noaf188. doi: 10.1093.
    PubMed     Abstract available
    
    
    
31. MAIR MJ, Werner JM, Weller J, Barci E, et al
    Prognostic stratification of newly diagnosed IDH-mutant gliomas by [18F]fluoroethyltyrosine and [11C]methionine PET - a retrospective, bicentric cohort study.
    Neuro Oncol. 2025 Aug 23:noaf196. doi: 10.1093.
    PubMed     Abstract available
    
    
    
32. JACOBSEN J, Locallo A, O'Rourke CJ, Carlsen JF, et al
    Clinical, Radiological, and Molecular Insights into Extracranial Metastases from Adult Gliomas.
    Neuro Oncol. 2025 Aug 16:noaf178. doi: 10.1093.
    PubMed     Abstract available
    
    
    
33. KALEY TJ, Grommes C, Coffee E, Young RJ, et al
    Multicenter basket trial for Central Nervous System tumors identifies activity of the CDK4/6 inhibitor abemaciclib in recurrent meningioma.
    Neuro Oncol. 2025 Aug 16:noaf184. doi: 10.1093.
    PubMed     Abstract available
    
    
    
34. WEN PY, Weller M, Lee EQ, Touat M, et al
    Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions.
    Neuro Oncol. 2025 Aug 13:noaf177. doi: 10.1093.
    PubMed     Abstract available
    
    
    
35. BELLAMY C, Hajal C, Ligon KL, Touat M, et al
    Revisiting an old therapy for new, promising combinations: biology and perspectives of lomustine in glioma treatment.
    Neuro Oncol. 2025 Aug 13:noaf192. doi: 10.1093.
    PubMed     Abstract available
    
    
    
36. PELLERINO A, Priego N, Bertero L, Ricci AA, et al
    STAT3 expression in brain metastases from breast cancer is correlated with molecular subtype and impacts clinical outcome.
    Neuro Oncol. 2025 Aug 9:noaf187. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2025
37. EL SHAFIE RA, Bernhardt D, Welzel T, Schiele A, et al
    Hypofractionated Stereotactic Radiotherapy versus Whole-Brain Radiotherapy following Brain Metastasis Resection - Results of the ESTRON Randomized Phase 2 Trial.
    Neuro Oncol. 2025 Jul 30:noaf182. doi: 10.1093.
    PubMed     Abstract available
    
    
    
38. YEI J, Lee NK, Ryu S, Ryu SE, et al
    Glioma-Associated Microglia Potentiate Neuronal Hyper-Excitability in the Glioma Environment.
    Neuro Oncol. 2025 Jul 30:noaf181. doi: 10.1093.
    PubMed     Abstract available
    
    
    
39. ZHAO J, Wu L, Cai G, Ou D, et al
    Targeting PGE2 mediated senescent neuron improves tumor therapy.
    Neuro Oncol. 2025;27:1491-1506.
    PubMed     Abstract available
    
    
    
40. WACH J, Basaran AE, Vychopen M, Tihan T, et al
    Local tumor control and neurological outcomes after surgery for spinal hemangioblastomas in sporadic and von Hippel-Lindau disease: A multicenter study.
    Neuro Oncol. 2025;27:1567-1578.
    PubMed     Abstract available
    
    
    
41. DE SOUSA GR, Calzadilla AJ, Grimaldo E, Donson AM, et al
    Loss of LDOC1 by chromatin compaction in mesenchymal tumor cells is required for PFA1 ependymoma growth.
    Neuro Oncol. 2025;27:1597-1610.
    PubMed     Abstract available
    
    
    
42. FAN C, Hu Y, Teng C, Lv Y, et al
    Intrathecal sintilimab for leptomeningeal metastases of non-small cell lung cancer failed from targeted therapy and intrathecal chemotherapy (LMIS study).
    Neuro Oncol. 2025;27:1559-1566.
    PubMed     Abstract available
    
    
    
43. DAS D, Iyer M, Nakamura B, Sedighi S, et al
    Tumor cells upregulate neurotransmitter GABA in the choroid plexus through STAT6-Bestrophin1 signaling, promoting leptomeningeal dissemination.
    Neuro Oncol. 2025;27:1476-1490.
    PubMed     Abstract available
    
    
    
44. AHMED KA, Kim Y, Armaghani AJ, Arrington JA, et al
    Phase II trial of brain MRI surveillance in stage IV breast cancer.
    Neuro Oncol. 2025;27:1550-1558.
    PubMed     Abstract available
    
    
    
45. DEAN F, Henrikson H, Xu R, Farah H, et al
    Challenges in determining the global burden of non-malignant central nervous system tumors: An analysis of international incidence and mortality data sources.
    Neuro Oncol. 2025;27:1654-1664.
    PubMed     Abstract available
    
    
    
46. MATSUMOTO Y, Singh O, Garcia J, Abdullaev Z, et al
    Intra-tumoral Preservation of the Stem-like Malignant Cell Proportion in Glioblastoma, Prognostic Impact, and its Radiomethylomic Signatures.
    Neuro Oncol. 2025 Jul 28:noaf175. doi: 10.1093.
    PubMed     Abstract available
    
    
    
47. 
    Erratum to: Golgi phosphoprotein 3 promotes glioma progression via inhibiting Rab5-mediated endocytosis and degradation of epidermal growth factor receptor.
    Neuro Oncol. 2025 Jul 28:noaf167. doi: 10.1093.
    PubMed    
    
    
    
48. GALLDIKS N, Tonn JC, Preusser M, Albert NL, et al
    Update to the RANO Working Group and EANO recommendations for the clinical use of PET imaging in gliomas.
    Neuro Oncol. 2025 Jul 28:noaf170. doi: 10.1093.
    PubMed    
    
    
    
49. PERREAULT S, Geurts M, Mahdi J, Schreck KC, et al
    Point/counterpoint: Upfront BRAF inhibition for adult BRAF-mutant high-grade gliomas.
    Neuro Oncol. 2025 Jul 26:noaf164. doi: 10.1093.
    PubMed    
    
    
    
50. 
    Erratum to: High-resolution proteomic analysis of medulloblastoma clinical samples identifies therapy-resistant subgroups and MYC immunohistochemistry as a powerful outcome predictor.
    Neuro Oncol. 2025 Jul 25:noaf150. doi: 10.1093.
    PubMed    
    
    
    
51. JOST-ENGL J, Ketter R, Brandt R, Volker K, et al
    Enhancing Cardiorespiratory Fitness and Quality of Life in High-Grade Glioma through an Intensive Exercise Intervention during Chemotherapy: Proof of Concept.
    Neuro Oncol. 2025 Jul 25:noaf176. doi: 10.1093.
    PubMed     Abstract available
    
    
    
52. PRICE M, Low JT, Chavez G, Conlon P, et al
    Improvements in survival for glioblastoma in the post-Stupp protocol era.
    Neuro Oncol. 2025 Jul 22:noaf134. doi: 10.1093.
    PubMed    
    
    
    
53. 
    Corrigendum to: Characterizing long-term neurocognitive outcomes through diffusion tensor imaging in childhood brain tumor survivors.
    Neuro Oncol. 2025 Jul 22:noaf161. doi: 10.1093.
    PubMed    
    
    
    
54. YOUNG JS, Berger MS, Lasocki A, Suwala AK, et al
    Point/counterpoint: The role of re-resection in recurrent glioblastoma.
    Neuro Oncol. 2025 Jul 21:noaf127. doi: 10.1093.
    PubMed    
    
    
    
55. VAN DEN BENT MJ, Cloughesy TF, Ellingson BM, Allen JE, et al
    The Use of Minor Response, Volumetric Assessment and Growth Rate Kinetics as Endpoints in Grade 1-3 Glioma Clinical Trials: a RANO perspective.
    Neuro Oncol. 2025 Jul 19:noaf173. doi: 10.1093.
    PubMed     Abstract available
    
    
    
56. VADLA R, Taylor B, Miyake Y, Lin B, et al
    BRD2 Bromodomain-Mediated Regulation of Cell State Plasticity Modulates Therapy Response in Glioblastoma.
    Neuro Oncol. 2025 Jul 19:noaf169. doi: 10.1093.
    PubMed     Abstract available
    
    
    
57. AVILA EK, Reiner AS, Armstrong TS, Aaroe AE, et al
    RANO seizure working group-Tumor Related Epilepsy Assessment Tool (RANO-TREAT) to assess seizure control for glioma treatment trials and clinical practice.
    Neuro Oncol. 2025 Jul 12:noaf165. doi: 10.1093.
    PubMed     Abstract available
    
    
    
58. ZHANG Y, Rabinovsky R, Deforzh E, Kobayashi A, et al
    Lipid nanoparticle formulation for gene editing and RNA-based therapies for glioblastoma.
    Neuro Oncol. 2025 Jul 11:noaf162. doi: 10.1093.
    PubMed     Abstract available
    
    
    
59. BOURMEAU G, Anezo O, Raymond J, Ballestin A, et al
    Proneural-Mesenchymal hybrid glioblastoma cells are resistant to therapy and dependent on nuclear import.
    Neuro Oncol. 2025 Jul 8:noaf160. doi: 10.1093.
    PubMed     Abstract available
    
    
    
60. 
    Correction to: Erratum to: TRLS-11. PNOC005: ONCOLYTIC MEASLES VIRUS FOR THE TREATMENT OF CHILDREN AND YOUNG ADULTS WITH RECURRENT MEDULLOBLASTOMA OR ATYPICAL TERATOID RHABDOID TUMOR.
    Neuro Oncol. 2025 Jul 1:noaf149. doi: 10.1093.
    PubMed    
    
    
    June 2025
61. SFERRUZZA G, Desingu K, Cubero Cruz A, Finocchiaro G, et al
    Assessing time-trend bias in glioblastoma prognosis over two decades of clinical trials.
    Neuro Oncol. 2025 Jun 28:noaf158. doi: 10.1093.
    PubMed     Abstract available
    
    
    
62. 
    Erratum to: Multi-site retrospective analysis of diffusion and perfusion magnetic resonance imaging correlates to glioma characteristics derived from radio-pathomic map.
    Neuro Oncol. 2025 Jun 28:noaf147. doi: 10.1093.
    PubMed    
    
    
    
63. 
    Erratum to: Raman-based machine-learning platform reveals unique metabolic differences between IDHmut and IDHwt glioma.
    Neuro Oncol. 2025 Jun 28:noaf139. doi: 10.1093.
    PubMed    
    
    
    
64. BREEN WG, Dixon JG, Anderson SK, Sarkaria JN, et al
    Final Report on NCCTG N0877 (Alliance): A Phase II Randomized, Placebo-Controlled Trial of Chemoradiotherapy with or without Dasatinib for Glioblastoma.
    Neuro Oncol. 2025 Jun 28:noaf156. doi: 10.1093.
    PubMed     Abstract available
    
    
    
65. RAMAPRIYAN R, Barker FG 2nd, Richardson LG, Sun J, et al
    Mesothelin is a surface antigen present on human meningioma and can be effectively targeted by CAR T-cells.
    Neuro Oncol. 2025 Jun 28:noaf155. doi: 10.1093.
    PubMed     Abstract available
    
    
    
66. LUO F, Mei Y, Li Y, Yang J, et al
    CAF-derived LRRC15 orchestrates macrophage polarization and limits PD-1 immunotherapy efficacy in glioblastoma.
    Neuro Oncol. 2025 Jun 26:noaf157. doi: 10.1093.
    PubMed     Abstract available
    
    
    
67. CORBETT RJ, Gullickson CC, Geng Z, Brown MA, et al
    Genetic ancestry superpopulations show distinct prevalence and outcomes across pediatric central nervous system tumors from the Pediatric Brain Tumor Atlas and Pediatric Neuro-Oncology Consortium.
    Neuro Oncol. 2025;27:1356-1371.
    PubMed     Abstract available
    
    
    
68. RIVIERE-CAZAUX C, Keough MB, Zuccato JA, Kumar R, et al
    A hitchhiker's guide to cerebrospinal fluid biomarkers for neuro-oncology.
    Neuro Oncol. 2025;27:1165-1179.
    PubMed     Abstract available
    
    
    
69. COLAES R, Blommaert J, Lambrecht M, de Ruiter MB, et al
    Hippocampal avoidance prophylactic cranial irradiation (HA-PCI) for small-cell lung cancer better preserves white matter networks compared to conventional PCI.
    Neuro Oncol. 2025;27:1285-1296.
    PubMed     Abstract available
    
    
    
70. REINECKE D, Maarouf N, Smith A, Alber D, et al
    Fast intraoperative detection of primary central nervous system lymphoma and differentiation from common central nervous system tumors using stimulated Raman histology and deep learning.
    Neuro Oncol. 2025;27:1297-1310.
    PubMed     Abstract available
    
    
    
71. GERRITSEN JKW, Karschnia P, Young JS, van den Bent MJ, et al
    Practical and statistical aspects of subgroup analyses in surgical neuro-oncology: A comprehensive review from the PIONEER consortium.
    Neuro Oncol. 2025;27:1149-1164.
    PubMed     Abstract available
    
    
    
72. PANG QY, Novera W, Koh LWH, Chong YK, et al
    Glioportal: a comprehensive transcriptomic resource unveiling ligand-mediated mesenchymal transition in glioblastoma.
    Neuro Oncol. 2025 Jun 16:noaf145. doi: 10.1093.
    PubMed     Abstract available
    
    
    
73. QIAN AS, Karunamuni R, Unnikrishnan S, Salans MA, et al
    Beyond the hippocampus: Limbic white matter injury implicated in post-radiation memory performance in primary brain tumor patients.
    Neuro Oncol. 2025 Jun 13:noaf144. doi: 10.1093.
    PubMed     Abstract available
    
    
    
74. SHARD C, Jones AC, Fouladzadeh A, Palethorpe HM, et al
    Novel GABAAR antagonists target networked gene hubs at the leading-edge in high-grade gliomas.
    Neuro Oncol. 2025 Jun 11:noaf143. doi: 10.1093.
    PubMed     Abstract available
    
    
    
75. 
    Erratum to: Phase 1 dose-escalation trial using convection-enhanced delivery of radio-immunotheranostic 124I-Omburtamab for diffuse intrinsic pontine glioma.
    Neuro Oncol. 2025 Jun 9:noaf138. doi: 10.1093.
    PubMed    
    
    
    
76. MAZEWSKI C, Leary SES, Kang G, Li BK, et al
    Phase 3 randomized trial of high-dose methotrexate for young children with high-risk embryonal brain tumors: A report from the Children's Oncology Group.
    Neuro Oncol. 2025 Jun 9:noaf132. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2025
77. SANVITO F, Kim A, Raymond C, Teraishi A, et al
    Impact of corticosteroid administration on contrast-enhancing volume and diffusion MRI in treatment naive glioblastoma.
    Neuro Oncol. 2025 May 30:noaf136. doi: 10.1093.
    PubMed     Abstract available
    
    
    
78. COOMBS MJ, Dowdy T, Alam MM, Vilamu HM, et al
    Glioblastoma-enriched glycosphingolipids modulate the function of human iNKT cells.
    Neuro Oncol. 2025 May 28:noaf135. doi: 10.1093.
    PubMed     Abstract available
    
    
    
79. TABATABAI G
    Expanding the Immunotherapeutic Toolbox in Glioblastoma: A Safe and Feasible Strategy at the Point of Surgery.
    Neuro Oncol. 2025 May 28:noaf124. doi: 10.1093.
    PubMed    
    
    
    
80. RANA AB, Horton TM, Thakur VS, Wang D, et al
    Polyamine acetylation mediates crosstalk between cancer cells and myeloid cells to promote mesenchymal/plurimetabolic states in glioblastoma.
    Neuro Oncol. 2025 May 27:noaf128. doi: 10.1093.
    PubMed     Abstract available
    
    
    
81. DENG MY, Maas SLN, Anil G, Sievers P, et al
    Postoperative radiotherapy in subtotally-resected recurrent WHO grade 1 meningiomas with intermediate-/high-risk molecular profiles.
    Neuro Oncol. 2025 May 27:noaf125. doi: 10.1093.
    PubMed     Abstract available
    
    
    
82. FOSTER JB, Madsen PJ, Harvey K, Griffin C, et al
    Transient mRNA CAR T cells targeting GD2 provide dose-adjusted efficacy against diffuse midline glioma and high grade glioma models.
    Neuro Oncol. 2025 May 24:noaf115. doi: 10.1093.
    PubMed     Abstract available
    
    
    
83. LIU Y, Peng Y, Song C, Liu Z, et al
    Tumor-associated macrophage-derived exosomes modulate the immunotherapeutic sensitivity of SHH-medulloblastoma by targeting m6A-modified FOXD1.
    Neuro Oncol. 2025 May 22:noaf123. doi: 10.1093.
    PubMed     Abstract available
    
    
    
84. SOBRAL LM, Walker FM, Madhavan K, Janko E, et al
    Targeting processive transcription for Myc-driven circuitry in medulloblastoma.
    Neuro Oncol. 2025 May 15:noaf121. doi: 10.1093.
    PubMed     Abstract available
    
    
    
85. SCHMID S, Mirchia K, Tietze A, Liu I, et al
    VGLL fusions define a new class of intraparenchymal central nervous system schwannoma.
    Neuro Oncol. 2025;27:1031-1045.
    PubMed     Abstract available
    
    
    
86. MARTIN B, Guadix SW, Sathian R, Laramee M, et al
    Designing a time-dependent therapeutic strategy using CDK4/6 inhibitors in an intracranial ATRT model.
    Neuro Oncol. 2025;27:1076-1091.
    PubMed     Abstract available
    
    
    
87. SUN N, Chen Q, Chen H, Sun P, et al
    A novel nuclear RNA HSD52 scaffolding NONO/SFPQ complex modulates DNA damage repair to facilitate temozolomide resistance.
    Neuro Oncol. 2025;27:963-978.
    PubMed     Abstract available
    
    
    
88. QIU J, Zhao R, Ma C, Wang Q, et al
    O-GlcNAcylation stabilized WTAP promotes GBM malignant progression in an N6-methyladenosine-dependent manner.
    Neuro Oncol. 2025;27:900-915.
    PubMed     Abstract available
    
    
    
89. GHOSH HS, Patel RV, Claus EB, Gonzalez Castro LN, et al
    Canonical amplifications and CDKN2A/B loss refine IDH1/2-mutant astrocytoma prognosis.
    Neuro Oncol. 2025;27:993-1003.
    PubMed     Abstract available
    
    
    
90. HAI L, Friedel D, Hinz F, Hoffmann DC, et al
    Distinct epigenetic and transcriptional profiles of Epstein-Barr virus-positive and negative primary CNS lymphomas.
    Neuro Oncol. 2025;27:979-992.
    PubMed     Abstract available
    
    
    
91. PIGNATTI F, Herold R, Demolis P, Rohr UP, et al
    Novel PET RANO BM 1.0 criteria: Regulatory perspectives on new endpoint definitions in brain metastases.
    Neuro Oncol. 2025 May 8:noaf067. doi: 10.1093.
    PubMed    
    
    
    
92. DAS A
    Consortium trial demonstrates efficacy of Selumetinib in pediatric low-grade glioma.
    Neuro Oncol. 2025 May 8:noaf119. doi: 10.1093.
    PubMed    
    
    
    
93. ANAND A, Petersen JK, Andersen LVB, Burton M, et al
    Multiomic profiling of glioblastoma metabolic lesions reveals complex intratumoral genomic evolution and dipeptidase-1-driven vascular proliferation.
    Neuro Oncol. 2025 May 4:noaf071. doi: 10.1093.
    PubMed     Abstract available
    
    
    
94. RAMASWAMY V, Tabori U
    Mind Over Microbes: Targeting the Gut-Brain Axis to Improve Treatment of Pediatric Low-Grade Glioma.
    Neuro Oncol. 2025 May 2:noaf094. doi: 10.1093.
    PubMed    
    
    
    
95. RUIZ-MORENO C, Salas SM, Samuelsson E, Minaeva M, et al
    Charting the Single-Cell and Spatial Landscape of IDH-Wildtype Glioblastoma with GBmap.
    Neuro Oncol. 2025 May 2:noaf113. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2025
96. NEJO T, Prins RM, Okada H
    The TCR Repertoire: A Window Into Pediatric Brain Tumor Immunity.
    Neuro Oncol. 2025 Apr 30:noaf112. doi: 10.1093.
    PubMed    
    
    
    
97. LIU S, Ma J
    Rethinking neurocognitive outcomes in adult survivors of childhood medulloblastoma: Progress and unmet challenges.
    Neuro Oncol. 2025 Apr 29:noaf051. doi: 10.1093.
    PubMed    
    
    
    
98. HOU D, Wang S, Castro BA, Katz JL, et al
    Dual alphaVbeta8 Integrin and PD-1 Blockade Overcomes TGFbeta-Mediated B-Cell Suppression to Enhance Anti-Glioma Immunity.
    Neuro Oncol. 2025 Apr 22:noaf106. doi: 10.1093.
    PubMed     Abstract available
    
    
    
99. WANG Z, Zhang Y, Wu F, Qiu B, et al
    Therapy-induced senescent glioblastoma cells sustain a procancer immune microenvironment by activating DDX58-mediated STAT1 signaling.
    Neuro Oncol. 2025 Apr 22:noaf107. doi: 10.1093.
    PubMed     Abstract available
    
    
    
100. SIEVERS P, Arora S, Hielscher T, Savran D, et al
     Molecular signatures define BAP1-altered meningioma as a distinct CNS tumor with deregulation of Polycomb repressive complex target genes.
     Neuro Oncol. 2025 Apr 18:noaf105. doi: 10.1093.
     PubMed     Abstract available
     
     
     
101. KHALILI BF, Dixit K, Kamson DO, Horbinski C, et al
     The excitatory milieu in glioma: mechanisms and therapeutic avenues.
     Neuro Oncol. 2025 Apr 18:noaf063. doi: 10.1093.
     PubMed     Abstract available
     
     
     
102. FANGUSARO J, Onar-Thomas A, Young Poussaint T, Lensing S, et al
     A Phase 2 PBTC Study of Selumetinib for Recurrent/Progressive Pediatric Low-Grade Glioma: Strata 2, 5, and 6 with Long-term Outcomes on Strata 1, 3, and 4.
     Neuro Oncol. 2025 Apr 17:noaf065. doi: 10.1093.
     PubMed     Abstract available
     
     
     
103. XUE Z, Mladek AC, Rathi S, Jain S, et al
     The novel brain penetrant ATM inhibitor WSD0628 provides robust radiosensitization of brain tumor patient derived xenografts.
     Neuro Oncol. 2025 Apr 15:noaf102. doi: 10.1093.
     PubMed     Abstract available
     
     
     
104. JUTTEN K, Ort J, Kernbach JM, Meyer-Baese A, et al
     High peritumoral network connectedness in glioblastoma reveals a distinct epigenetic signature and is associated with decreased overall survival.
     Neuro Oncol. 2025 Apr 15:noaf101. doi: 10.1093.
     PubMed     Abstract available
     
     
     
105. HUNG CY, Kang EY, Jacek K, Yu C, et al
     Multimodal glioma immunotherapy combining TLR9-targeted STAT3 antisense oligodeoxynucleotides with PD1 immune checkpoint blockade.
     Neuro Oncol. 2025 Apr 11:noaf099. doi: 10.1093.
     PubMed     Abstract available
     
     
     
106. WANG Y, Chen Z, Li R, Wei D, et al
     S-palmitoylation of c-MET by CK2alpha-mediated zDHHC15 phosphorylation drives glioblastoma stem cell tumorigenicity.
     Neuro Oncol. 2025 Apr 10:noaf098. doi: 10.1093.
     PubMed     Abstract available
     
     
     
107. GUO Y, Li Z, Parsels LA, Wang Z, et al
     H3K27M diffuse midline glioma is homologous recombination defective and sensitized to radiotherapy and NK cell-mediated antitumor immunity by PARP inhibition.
     Neuro Oncol. 2025 Apr 10:noaf097. doi: 10.1093.
     PubMed     Abstract available
     
     
     
108. ERKER C, Mynarek M, Simbozel M, Craig BT, et al
     Salvage therapies for first relapse of SHH medulloblastoma in early childhood.
     Neuro Oncol. 2025 Apr 4:noaf092. doi: 10.1093.
     PubMed     Abstract available
     
     
     
109. RESSA G, Levi R, Savini G, Raspagliesi L, et al
     AI differentiates radionecrosis from true progression in brain metastasis upon stereotactic radiosurgery: analysis of 124 histologically assessed lesions.
     Neuro Oncol. 2025 Apr 2:noaf090. doi: 10.1093.
     PubMed     Abstract available
     
     
     
110. CHAN P, Nagai Y, Wu Q, Hovsepyan A, et al
     Advancing Clinical Response Against Glioblastoma: Evaluating SHP1705 CRY2 Activator Efficacy in Preclinical Models and Safety in Phase I Trials.
     Neuro Oncol. 2025 Apr 1:noaf089. doi: 10.1093.
     PubMed     Abstract available
     
     
     March 2025
111. HOANG TT, Schraw JM, Shumate C, Desrosiers TA, et al
     Co-occurrence of congenital anomalies and childhood brain tumors in 22 million live births.
     Neuro Oncol. 2025 Mar 26:noaf087. doi: 10.1093.
     PubMed     Abstract available
     
     
     
112. YU X, Song X, Tiek D, Wu R, et al
     Targeting PDGFRA-SHP2 Signaling Enhances Radiotherapy in IDH1-Mutant Glioma.
     Neuro Oncol. 2025 Mar 25:noaf086. doi: 10.1093.
     PubMed     Abstract available
     
     
     
113. DIAZ-FERNANDEZ B, Henao-Herreno D, Nieto J, Evstratova A, et al
     Differentiation of Tumor vs. Peritumoral Cortex in Gliomas by Intraoperative Electrocorticography.
     Neuro Oncol. 2025 Mar 24:noaf082. doi: 10.1093.
     PubMed     Abstract available
     
     
     
114. WEN PY, Manzanera A, Duault C, Gonzalez-Kozlova E, et al
     A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastoma.
     Neuro Oncol. 2025 Mar 22:noaf079. doi: 10.1093.
     PubMed     Abstract available
     
     
     
115. CONKLIN HM, Salman NA, Bass JK, Huang J, et al
     Ototoxicity and Cognitive Outcomes among Very Young Children Treated for Brain Tumors: Findings from a Multisite, Prospective, Longitudinal Trial.
     Neuro Oncol. 2025 Mar 22:noaf073. doi: 10.1093.
     PubMed     Abstract available
     
     
     
116. SANVITO F, Nocera G, Wang Z, Shiuan E, et al
     Diffusion and contrast-enhancement MRI phenotypes associated with immune checkpoint inhibitor exposure and with immune cell infiltration in brain metastases.
     Neuro Oncol. 2025 Mar 22:noaf084. doi: 10.1093.
     PubMed     Abstract available
     
     
     
117. OGLESBY RT, Pathiravasan CH, Olatunji E, Chang L, et al
     Characterizing long-term neurocognitive outcomes through diffusion tensor imaging in childhood brain tumor survivors.
     Neuro Oncol. 2025 Mar 22:noaf083. doi: 10.1093.
     PubMed     Abstract available
     
     
     
118. FOLTYN-DUMITRU M, Banan R, Schell M, Mahmutoglu MA, et al
     Histopathological and molecular characteristics of IDH-wildtype glioblastoma without contrast enhancement: implications for clinical outcomes.
     Neuro Oncol. 2025 Mar 20:noaf070. doi: 10.1093.
     PubMed     Abstract available
     
     
     
119. XUE Z, Zhang X, Mao B, Mu G, et al
     Dual role of WNT10A in promoting the malignancy of glioblastoma and remodeling the tumor microenvironment.
     Neuro Oncol. 2025 Mar 18:noaf075. doi: 10.1093.
     PubMed     Abstract available
     
     
     
120. LI F, Bondra KM, Wang H, Kurmashev D, et al
     Dual Inhibition of MAPK and TORC1 Signaling Retards Development of Radiation Resistance in Pediatric BRAFV600E Glioma Models.
     Neuro Oncol. 2025 Mar 14:noaf068. doi: 10.1093.
     PubMed     Abstract available
     
     
     
121. MATEOS MK, Ajuyah P, Fuentes-Bolanos N, El-Kamand S, et al
     Germline analysis of an international cohort of pediatric diffuse midline glioma patients.
     Neuro Oncol. 2025 Mar 12:noaf061. doi: 10.1093.
     PubMed     Abstract available
     
     
     
122. 
     Corrigendum to: Targeting the cell cycle to enhance chemotherapy efficacy in glioblastoma.
     Neuro Oncol. 2025 Mar 10:noaf034. doi: 10.1093.
     PubMed    
     
     
     
123. 
     Corrigendum to: Suppression of glioblastoma by targeting the overactivated protein neddylation pathway.
     Neuro Oncol. 2025 Mar 10:noaf053. doi: 10.1093.
     PubMed    
     
     
     
124. JALALI R, Ghosh S, Chatterjee A, Goswami S, et al
     High-precision radiotherapy achieves excellent long-term control and preserves function in pediatric craniopharyngioma - Subset analysis of a randomized trial.
     Neuro Oncol. 2025 Mar 8:noaf049. doi: 10.1093.
     PubMed     Abstract available
     
     
     
125. LIU Y, Liu F, Li C, Zhang T, et al
     TRIM21-mediated ubiquitination and phosphorylation of ERK1/2 promotes cell proliferation and drug resistance in pituitary adenomas.
     Neuro Oncol. 2025;27:727-742.
     PubMed     Abstract available
     
     
     
126. TAKAMI H, Matsutani M, Suzuki T, Takabatake K, et al
     Phase II trial of pathology-based tripartite treatment stratification for patients with CNS germ cell tumors: A long-term follow-up study.
     Neuro Oncol. 2025;27:828-840.
     PubMed     Abstract available
     
     
     
127. AKDEMIR EY, Gurdikyan S, Rubens M, Abrams KJ, et al
     Efficacy of 3D-TSE sequence-based radiosurgery in prolonging time to distant intracranial failure: A session-wise analysis in a histology-diverse patient cohort.
     Neuro Oncol. 2025;27:854-864.
     PubMed     Abstract available
     
     
     
128. FIGARELLA-BRANGER D, Colin C, Mokhtari K, Uro-Coste E, et al
     Reappraisal of prognostic factors in CNS WHO grade 3 oligodendrogliomas IDH-mutant and 1p/19q co-deleted: Lessons from the French POLA cohort.
     Neuro Oncol. 2025;27:755-766.
     PubMed     Abstract available
     
     
     
129. DELAIDELLI A, Burwag F, Ben-Neriah S, Suk Y, et al
     High-resolution proteomic analysis of medulloblastoma clinical samples identifies therapy resistant subgroups and MYC immunohistochemistry as a powerful outcome predictor.
     Neuro Oncol. 2025 Mar 5:noaf046. doi: 10.1093.
     PubMed     Abstract available
     
     
     
130. HADDADI AVVAL A, Banerjee S, Zielke J, Kann B, et al
     Applications of Artificial Intelligence and Advanced Imaging in Pediatric Diffuse Midline Glioma.
     Neuro Oncol. 2025 Mar 3:noaf058. doi: 10.1093.
     PubMed     Abstract available
     
     
     
131. DREXLER R, Lim M, Hervey-Jumper SL
     Molecular-based decision-making in glioblastoma surgery: when to aim for supramaximal resection.
     Neuro Oncol. 2025 Mar 3:noaf062. doi: 10.1093.
     PubMed     Abstract available
     
     
     February 2025
132. LIN K, Zou C, Hubbard A, Sengelmann S, et al
     Multiplexed epigenetic memory editing using CRISPRoff sensitizes glioblastoma to chemotherapy.
     Neuro Oncol. 2025 Feb 25:noaf055. doi: 10.1093.
     PubMed     Abstract available
     
     
     
133. DENG Y, Yuan Z, Jin X, Wang Z, et al
     Synapsin III promotes neuronal-like transdifferentiation of glioblastoma stem cells by disrupting JAG1-Notch1 interaction.
     Neuro Oncol. 2025 Feb 25:noaf056. doi: 10.1093.
     PubMed     Abstract available
     
     
     
134. SHERWOOD PR
     An opportunity to impact anxiety in family caregivers of persons with a primary malignant brain tumor.
     Neuro Oncol. 2025 Feb 24:noaf048. doi: 10.1093.
     PubMed    
     
     
     
135. 
     Corrigendum to: The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma.
     Neuro Oncol. 2025 Feb 19:noaf032. doi: 10.1093.
     PubMed    
     
     
     
136. SOUWEIDANE MM, Bander ED, Zanzonico P, Reiner AS, et al
     Phase 1 dose-escalation trial using convection-enhanced delivery (CED) of radio-immunotheranostic 124I-Omburtamab for diffuse intrinsic pontine glioma (DIPG).
     Neuro Oncol. 2025 Feb 19:noaf039. doi: 10.1093.
     PubMed     Abstract available
     
     
     
137. ELLENBOGEN Y, Taslimi S, Shellenberger J, Brogly SB, et al
     End-of-Life Care in Glioblastoma: A Population-Based Study.
     Neuro Oncol. 2025 Feb 19:noaf043. doi: 10.1093.
     PubMed     Abstract available
     
     
     
138. BOBHOLZ SA, Aaronsen D, Winiarz A, Duenweg SR, et al
     Multi-Site Retrospective Analysis of Diffusion and Perfusion MRI Correlates to Glioma Characteristics Derived from Radio-Pathomic Maps.
     Neuro Oncol. 2025 Feb 17:noaf044. doi: 10.1093.
     PubMed     Abstract available
     
     
     
139. LI J, Liu H, Wang Z, Zhang J, et al
     Unveiling spatial heterogeneity in medulloblastoma: a multi-omics analysis of cellular state and geographical organization.
     Neuro Oncol. 2025 Feb 17:noaf020. doi: 10.1093.
     PubMed     Abstract available
     
     
     
140. ANGURAJ VADIVEL AK, Pajovic S, Siddaway R, Zhu S, et al
     The proteomic landscape of diffuse midline glioma highlights the therapeutic potential of non-histone protein methyltransferases.
     Neuro Oncol. 2025 Feb 15:noaf033. doi: 10.1093.
     PubMed     Abstract available
     
     
     
141. LI X, Sun W, Guo Z, Qi F, et al
     Identification of Urinary Metabolic Biomarkers for H3K27M Mutation Diagnosis in Brainstem Gliomas.
     Neuro Oncol. 2025 Feb 14:noaf038. doi: 10.1093.
     PubMed     Abstract available
     
     
     
142. XIONG Z, Walsh KM, Sneiderman CT, Nisnboym M, et al
     Immuno-epidemiologic mapping of HLA diversity across glioma patient cohorts.
     Neuro Oncol. 2025 Feb 14:noaf040. doi: 10.1093.
     PubMed     Abstract available
     
     
     
143. HU J, Bao H, Liu X, Fang S, et al
     Glioma-White Matter Tract Interactions: A dMRI-Based Three-Tier Classification and Its Clinical Relevance.
     Neuro Oncol. 2025 Feb 13:noaf036. doi: 10.1093.
     PubMed     Abstract available
     
     
     
144. SHI T, Kujawa A, Linares C, Vercauteren T, et al
     Automated longitudinal treatment response assessment of brain tumors: a systematic review.
     Neuro Oncol. 2025 Feb 12:noaf037. doi: 10.1093.
     PubMed     Abstract available
     
     
     
145. STEINDL A, Valiente M
     Potential of ex vivo organotypic slice cultures in neuro-oncology.
     Neuro Oncol. 2025;27:338-351.
     PubMed     Abstract available
     
     
     
146. DAR D, Rodak M, Da Pieve C, Gorczewska I, et al
     Imaging PD-L1 in the brain-Journey from the lab to the clinic.
     Neuro Oncol. 2025;27:567-582.
     PubMed     Abstract available
     
     
     
147. MURPHY ES, Sahgal A, Regis J, Levivier M, et al
     Pediatric cranial stereotactic radiosurgery: Meta-analysis and international stereotactic radiosurgery society practice guidelines.
     Neuro Oncol. 2025;27:517-532.
     PubMed     Abstract available
     
     
     
148. LE RHUN E, Nayak L, Lim-Fat MJ, Ruda R, et al
     NANO-LM: An updated scorecard for the clinical assessment of patients with leptomeningeal metastases.
     Neuro Oncol. 2025;27:455-465.
     PubMed     Abstract available
     
     
     
149. RAHMAN R, Ventz S, Redd R, Fell G, et al
     Identifying appropriate external control datasets in support of future glioblastoma clinical trials leveraging external data.
     Neuro Oncol. 2025 Feb 8:noaf031. doi: 10.1093.
     PubMed     Abstract available
     
     
     
150. AN W, Li S, An Y, Lin Z, et al
     Molecular subtypes of adamantinomatous craniopharyngiomas.
     Neuro Oncol. 2025 Feb 3:noaf030. doi: 10.1093.
     PubMed     Abstract available
     
     
     
151. THOMAS MPH, Ajaib S, Tanner G, Bulpitt AJ, et al
     GBMPurity: A Machine Learning Tool for Estimating Glioblastoma Tumour Purity from Bulk RNA-seq Data.
     Neuro Oncol. 2025 Feb 1:noaf026. doi: 10.1093.
     PubMed     Abstract available
     
     
     January 2025
152. GREENBERG I, Khair F, Merenbakh-Lamin K, Sokol E, et al
     IRS2 as a driver of brain metastasis in colorectal cancer: a potential target for novel therapeutic strategies.
     Neuro Oncol. 2025 Jan 31:noaf028. doi: 10.1093.
     PubMed     Abstract available
     
     
     
153. TAMBORINI M, Ribecco V, Stanzani E, Sironi A, et al
     Extracellular Vesicles Released by Glioblastoma Cancer Cells Drive Tumor Invasiveness via Connexin-43 Gap Junctions.
     Neuro Oncol. 2025 Jan 30:noaf013. doi: 10.1093.
     PubMed     Abstract available
     
     
     
154. 
     Erratum to: Maternal obesogenic diet operates at the tumor cell of origin to increase incidence and decrease latency of neurofibromatosis type 1 optic pathway glioma.
     Neuro Oncol. 2025 Jan 29:noaf010. doi: 10.1093.
     PubMed    
     
     
     
155. CHEN YM, Chambon J, Moquin A, Hashimoto M, et al
     Nanoparticle encapsulation enables systemic IGF-Trap delivery to inhibit intra-cerebral glioma growth.
     Neuro Oncol. 2025 Jan 29:noaf011. doi: 10.1093.
     PubMed     Abstract available
     
     
     
156. ZHANG X, Jiang M, Niu W, Xu B, et al
     CircPRKD3-loaded exosomes concomitantly elicit tumor growth inhibition and glioblastoma microenvironment remodeling via inhibiting STAT3 signaling.
     Neuro Oncol. 2025 Jan 27:noaf019. doi: 10.1093.
     PubMed     Abstract available
     
     
     
157. CHATTERJEE J, Qi X, Mu R, Li X, et al
     Intestinal Bacteroides drives glioma progression by regulating CD8+ T cell tumor infiltration.
     Neuro Oncol. 2025 Jan 27:noaf024. doi: 10.1093.
     PubMed     Abstract available
     
     
     
158. LANDRY AP, Wang JZ, Yefet LS, Liu J, et al
     Metabolic profiling of meningioma reveals novel subgroup-specific biologic insights and outcome dependencies.
     Neuro Oncol. 2025 Jan 24:noae281. doi: 10.1093.
     PubMed     Abstract available
     
     
     
159. DE LA FUENTE MI, Lassman AB
     Pre-Radiation Targeted Therapy for Highly Selected Patients with Newly Diagnosed Glioblastoma: New Tricks for an Old Dog?
     Neuro Oncol. 2025 Jan 24:noaf014. doi: 10.1093.
     PubMed    
     
     
     
160. LE RHUN E, Bink A, Felsberg J, Gramatzki D, et al
     The clinical and molecular landscape of diffuse hemispheric glioma, H3 G34-mutant.
     Neuro Oncol. 2025 Jan 22:noaf015. doi: 10.1093.
     PubMed     Abstract available
     
     
     
161. KOTECHA R, Akdemir EY, Kutuk T, Ilgin C, et al
     Benchmarking the Efficacy of Salvage Systemic Therapies for Recurrent Meningioma: A RANO Group Systematic Review and Meta-analysis to Guide Clinical Trial Design.
     Neuro Oncol. 2025 Jan 14:noaf009. doi: 10.1093.
     PubMed     Abstract available
     
     
     
162. PASCOE M, Byrne E, King A, Cooper D, et al
     Sleep disorders associated with cranial radiation-A systematic review.
     Neuro Oncol. 2025;27:63-76.
     PubMed     Abstract available
     
     
     
163. LIM-FAT MJ, Bennett J, Ostrom Q, Touat M, et al
     Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology Consensus Review on diagnosis, management, and future directions.
     Neuro Oncol. 2025;27:13-32.
     PubMed     Abstract available
     
     
     
164. HO KH, Trapp M, Guida C, Ivanova EL, et al
     Activation of Wnt/beta-catenin signaling is critical for the tumorigenesis of choroid plexus.
     Neuro Oncol. 2025;27:106-122.
     PubMed     Abstract available
     
     
     
165. MIRCHIA K, Choudhury A, Joseph T, Birrueta JO, et al
     Meningeal solitary fibrous tumor cell states phenocopy cerebral vascular development and homeostasis.
     Neuro Oncol. 2025;27:155-166.
     PubMed     Abstract available
     
     
     
166. OBRECHT-STURM D, Schoof M, Eckhardt A, Mynarek M, et al
     Distinct relapse pattern across molecular ependymoma types.
     Neuro Oncol. 2025;27:267-276.
     PubMed     Abstract available
     
     
     
167. CHAUDHARY S, Das U, Jabbar S, Gangisetty O, et al
     Developmental pluripotency-associated 4 increases aggressiveness of pituitary neuroendocrine tumors by enhancing cell stemness.
     Neuro Oncol. 2025;27:123-139.
     PubMed     Abstract available
     
     
     
168. LAWLER SE
     Tracing tumor-neuronal connectivity in glioblastoma.
     Neuro Oncol. 2025 Jan 11:noaf005. doi: 10.1093.
     PubMed    
     
     
     
169. MARTELL E, Kuzmychova H, Senthil H, Chawla U, et al
     Disease stage-specific role of the mitochondrial pyruvate carrier suppresses differentiation in temozolomide and radiation-treated glioblastoma.
     Neuro Oncol. 2025 Jan 11:noaf008. doi: 10.1093.
     PubMed     Abstract available
     
     
     
170. DELIGNE C, Tourbez A, Benard F, Meyer S, et al
     Establishing a living biobank of pediatric high-grade glioma and ependymoma suitable for cancer pharmacology.
     Neuro Oncol. 2025 Jan 10:noaf007. doi: 10.1093.
     PubMed     Abstract available
     
     
     
171. ZHANG K, Touat M, Khasraw M
     KL-50: A Novel Therapeutic Agent Targeting MGMT-Deficient Glioblastoma.
     Neuro Oncol. 2025 Jan 8:noaf001. doi: 10.1093.
     PubMed    
     
     
     
172. RALEIGH DR
     Genomic features underlying meningioma sex-specificity.
     Neuro Oncol. 2025 Jan 8:noaf002. doi: 10.1093.
     PubMed    
     
     
     
173. LANDRY AP, Wang JZ, Liu J, Patil V, et al
     Development and validation of a molecular classifier of meningiomas.
     Neuro Oncol. 2025 Jan 8:noae242. doi: 10.1093.
     PubMed     Abstract available
     
     
     
174. GROFF KJ, Snuderl M
     Predicting recurrence of meningioma using DNA methylation for clinical practice.
     Neuro Oncol. 2025 Jan 8:noaf003. doi: 10.1093.
     PubMed    
     
     
     
175. HAEUSSER LA, Becker H, Kuhlburger L, Zago M, et al
     Genome-wide CRISPR-Cas 9 screens identify BCL family members as modulators of response to regorafenib in experimental glioma.
     Neuro Oncol. 2025 Jan 4:noae278. doi: 10.1093.
     PubMed     Abstract available
     
     
     
176. GUERRA G, Wendt G, McCoy L, Hansen HM, et al
     Functional germline variants in DNA damage repair pathways are associated with altered survival in adults with glioma treated with temozolomide.
     Neuro Oncol. 2025 Jan 2:noae275. doi: 10.1093.
     PubMed     Abstract available
     
     
     December 2024
177. RIVIERE-CAZAUX C, Graser CJ, Warrington AE, Hoplin MD, et al
     A field resource for the glioma cerebrospinal fluid proteome: impacts of resection and location on biomarker discovery.
     Neuro Oncol. 2024 Dec 30:noae277. doi: 10.1093.
     PubMed     Abstract available
     
     
     
178. FILSER M, Torrejon J, Merchadou K, Dufour C, et al
     Nanopore Sequencing as a Cutting-Edge Technology for Medulloblastoma Classification.
     Neuro Oncol. 2024 Dec 28:noae279. doi: 10.1093.
     PubMed     Abstract available
     
     
     
179. TANG Y, Sprinzen L, Terada Y, Kiang KM, et al
     Autophagy Modulates Glioblastoma Cell Sensitivity to Selinexor-mediated XPO1 inhibition.
     Neuro Oncol. 2024 Dec 28:noae280. doi: 10.1093.
     PubMed     Abstract available
     
     
     
180. RENOULT O, Laurent-Blond M, Pecqueur C
     Inhibiting glioblastoma stem cells by targeting pyruvate carboxylase: A novel therapeutic strategy with both opportunities and challenges.
     Neuro Oncol. 2024 Dec 26:noae250. doi: 10.1093.
     PubMed    
     
     
     
181. CHEN M, Mu G, Wu Y, Bjerkvig R, et al
     Inhibiting glioblastoma stem cells by targeting pyruvate carboxylase: a novel therapeutic strategy with both opportunities and challenges.
     Neuro Oncol. 2024 Dec 26:noae249. doi: 10.1093.
     PubMed    
     
     
     
182. TESKE NC, Jung LB, Teske N, Thon N, et al
     The inconsistent terminology for the extent of resection in glioblastoma: A systematic review on 6 decades of neuro-oncological studies.
     Neuro Oncol. 2024 Dec 26:noae254. doi: 10.1093.
     PubMed    
     
     
     
183. DE LA FUENTE MI, Touat M, van den Bent MJ, Preusser M, et al
     The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma.
     Neuro Oncol. 2024 Dec 25:noae259. doi: 10.1093.
     PubMed     Abstract available
     
     
     
184. NYSOM K, Kilburn LB, Leary SES, Landi DB, et al
     Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial.
     Neuro Oncol. 2024 Dec 19:noae274. doi: 10.1093.
     PubMed     Abstract available
     
     
     
185. AKBARI H, Bakas S, Sako C, Fathi Kazerooni A, et al
     Machine Learning-based Prognostic Subgrouping of Glioblastoma: A Multi-center Study.
     Neuro Oncol. 2024 Dec 12:noae260. doi: 10.1093.
     PubMed     Abstract available
     
     
     
186. 
     Corrigendum to: Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival.
     Neuro Oncol. 2024 Dec 10:noae244. doi: 10.1093.
     PubMed    
     
     
     
187. MCCORD M, Sears T, Wang W, Chaliparambil R, et al
     The novel DNA cross-linking agent KL-50 is active against patient-derived models of new and recurrent post-temozolomide mismatch repair-deficient glioblastoma.
     Neuro Oncol. 2024 Dec 10:noae257. doi: 10.1093.
     PubMed     Abstract available
     
     
     
188. WEN PY, Preusser M, Albert NL
     Design and conduct of theranostic trials in neuro-oncology: Challenges and opportunities.
     Neuro Oncol. 2024;26.
     PubMed     Abstract available
     
     
     
189. CICONE F, Gnesin S, Santo G, Stokke C, et al
     Do we need dosimetry for the optimization of theranostics in CNS tumors?
     Neuro Oncol. 2024;26.
     PubMed     Abstract available
     
     
     
190. LE RHUN E, Albert NL, Hullner M, Franceschi E, et al
     Targeted radionuclide therapy for patients with central nervous system metastasis: Overlooked potential?
     Neuro Oncol. 2024;26.
     PubMed     Abstract available
     
     
     
191. 
     Erratum to: Intracranial administration of anti-PD-1 and anti-CTLA-4 immune checkpoint-blocking monoclonal antibodies in patients with recurrent high-grade glioma.
     Neuro Oncol. 2024 Dec 7:noae256. doi: 10.1093.
     PubMed    
     
     
     
192. GALLOTTI AL, Rossi M, Conti Nibali M, Sciortino T, et al
     Neuro-Oncological Superiority of Supratotal Resection in Lower-Grade Gliomas.
     Neuro Oncol. 2024 Dec 7:noae264. doi: 10.1093.
     PubMed     Abstract available
     
     
     
193. TESKE N, Schnell O, Karschnia P
     Navigating in the dark:tailoring the extent of resection in gliomas with FastGlioma.
     Neuro Oncol. 2024 Dec 5:noae263. doi: 10.1093.
     PubMed    
     
     
     
194. LUO N, Zhu W, Li X, Fu M, et al
     Defective autophagy of pericytes enhances radiation-induced senescence promoting radiation brain injury.
     Neuro Oncol. 2024;26:2288-2304.
     PubMed     Abstract available
     
     
     
195. VAN DER WEL JWT, Boelens MC, Jebbink M, Smulders SA, et al
     Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of epidermal growth factor receptor-mutated non-small-cell lung carcinoma patients developing leptomeningeal metastases: Osimertinib Resistance Analysis-leptomeningeal metastases stud
     Neuro Oncol. 2024;26:2316-2327.
     PubMed     Abstract available
     
     
     
196. OH M, Cho H, Park JE, Kim HS, et al
     Enhancing prognostication and treatment response evaluation in primary CNS lymphoma with 18F-FDG-PET/CT.
     Neuro Oncol. 2024;26:2377-2387.
     PubMed     Abstract available
     
     
     
197. CHENG VWT, Heywood R, Zakaria R, Burger R, et al
     BMScope: A scoping review to chart the evolving clinical study landscape in brain and leptomeningeal metastasis.
     Neuro Oncol. 2024;26:2193-2207.
     PubMed     Abstract available
     
     
     
198. LIU APY, Li BK, Vasiljevic A, Dewan MC, et al
     SNO-EANO-EURACAN consensus on management of pineal parenchymal tumors.
     Neuro Oncol. 2024;26:2159-2173.
     PubMed     Abstract available
     
     
     
199. DUMOT C, Mantziaris G, Dayawansa S, Brantley C, et al
     Risk of new tumor, carotid stenosis, and stroke after stereotactic radiosurgery for pituitary tumor: A multicenter study of 2254 patients with imaging follow-up.
     Neuro Oncol. 2024;26:2328-2338.
     PubMed     Abstract available
     
     
     November 2024
200. SHEN H, Mudassar F, Ma S, Wang X, et al
     Inhibition of Mitochondrial Bioenergetics and Hypoxia to Radiosensitize Diffuse Intrinsic Pontine Glioma.
     Neuro Oncol. 2024 Nov 22:noae255. doi: 10.1093.
     PubMed     Abstract available
     
     
     
201. SAHM F, Bertero L, Brandner S, Capper D, et al
     EANO guideline on molecular testing of meningiomas for targeted therapy selection.
     Neuro Oncol. 2024 Nov 22:noae253. doi: 10.1093.
     PubMed     Abstract available
     
     
     
202. DHARMAIAH S, Malgulwar PB, Johnson WE, Chen BA, et al
     G-quadruplex stabilizer CX-5461 effectively combines with radiotherapy to target ATRX-deficient malignant glioma.
     Neuro Oncol. 2024 Nov 21:noae248. doi: 10.1093.
     PubMed     Abstract available
     
     
     
203. TABATABAI G, Platten M, Preusser M, Weller M, et al
     Treatment of glioblastoma patients with personalized vaccines outside clinical trials: Lessons ignored?
     Neuro Oncol. 2024 Nov 19:noae225. doi: 10.1093.
     PubMed    
     
     
     
204. MULLER KJ, Forbrig R, Reis J, Wiegand L, et al
     Measurable disease as baseline criterion for response assessment in glioblastoma: A comparison of PET -based (PET RANO 1.0) and MRI-based (RANO) assessments.
     Neuro Oncol. 2024 Nov 19:noae208. doi: 10.1093.
     PubMed     Abstract available
     
     
     
205. SARNOW K, Majercak E, Qurbonov Q, Cruzeiro GAV, et al
     Neuroimmune-competent human brain organoid model of Diffuse Midline Glioma.
     Neuro Oncol. 2024 Nov 19:noae245. doi: 10.1093.
     PubMed     Abstract available
     
     
     
206. KARAJANNIS MA, Onar-Thomas A, Lin T, Baxter PA, et al
     Phase 2 Trial of Veliparib, Local Irradiation and Temozolomide in Patients with Newly Diagnosed High-Grade Glioma: A Children's Oncology Group Study.
     Neuro Oncol. 2024 Nov 19:noae247. doi: 10.1093.
     PubMed     Abstract available
     
     
     
207. LUCAS CG, Al-Adli NN, Young JS, Gupta R, et al
     Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responses.
     Neuro Oncol. 2024 Nov 19:noae214. doi: 10.1093.
     PubMed     Abstract available
     
     
     
208. LAEMMERER A, Lehmann C, Mayr L, Bruckner K, et al
     Alternative lengthening of telomere-based immortalization renders H3G34R -mutant diffuse hemispheric glioma hypersensitive to PARP inhibitor combination regimens.
     Neuro Oncol. 2024 Nov 18:noae228. doi: 10.1093.
     PubMed     Abstract available
     
     
     
209. STRAUSS JD, Gilbert MR, Mehta M, Li A, et al
     Clinical and Genetic Markers of Vascular Toxicity in Glioblastoma Patients: Insights from NRG Oncology RTOG-0825.
     Neuro Oncol. 2024 Nov 16:noae234. doi: 10.1093.
     PubMed     Abstract available
     
     
     
210. WELLER J, Kocakavuk E, Pregler B, Zeyen T, et al
     Gene expression signature-defined necroinflammation is not associated with sex-biased survival or bevacizumab benefit in glioblastoma.
     Neuro Oncol. 2024 Nov 15:noae216. doi: 10.1093.
     PubMed    
     
     
     
211. BERGHAUS N, Hielscher T, Savran D, Schrimpf D, et al
     Meningiomas: Sex-Specific Differences and Prognostic Implications of a Chromosome X Loss.
     Neuro Oncol. 2024 Nov 13:noae239. doi: 10.1093.
     PubMed     Abstract available
     
     
     
212. BAZER DA, Wolff AC, Grossman SA
     Using a Pre-Radiation Window to Identify Potentially Active Cytotoxic Agents in Adults with Newly Diagnosed Glioblastoma.
     Neuro Oncol. 2024 Nov 13:noae240. doi: 10.1093.
     PubMed     Abstract available
     
     
     
213. IPPEN FM, Hielscher T, Friedel D, Gobel K, et al
     The prognostic impact of CDKN2A/B hemizygous deletions in IDH-mutant glioma.
     Neuro Oncol. 2024 Nov 12:noae238. doi: 10.1093.
     PubMed     Abstract available
     
     
     
214. RAHMAN R, Preusser M, Tsien C, Le Rhun E, et al
     Point/Counterpoint: The role of reirradiation in recurrent glioblastoma.
     Neuro Oncol. 2024 Nov 11:noae209. doi: 10.1093.
     PubMed    
     
     
     
215. GUI Y, Qin H, Zhang X, Chen Q, et al
     Glioma-Astrocyte connexin43 confers temozolomide resistance through activation of the E2F1/ERCC1 axis.
     Neuro Oncol. 2024 Nov 8:noae237. doi: 10.1093.
     PubMed     Abstract available
     
     
     
216. LANDRY AP, Wang JZ, Patil V, Gui C, et al
     Validation and next-generation update of a DNA methylation-based recurrence predictor for meningioma: a multicenter prospective study.
     Neuro Oncol. 2024 Nov 6:noae236. doi: 10.1093.
     PubMed     Abstract available
     
     
     
217. KOTECHA R, La Rosa A, Brown PD, Vogelbaum MA, et al
     Multidisciplinary management strategies for recurrent brain metastasis after prior radiotherapy: An overview.
     Neuro Oncol. 2024 Nov 4:noae220. doi: 10.1093.
     PubMed     Abstract available
     
     
     
218. KARSCHNIA P, Young JS, Youssef GC, Dono A, et al
     Development and validation of a clinical risk model for postoperative outcome in newly diagnosed glioblastoma: a report of the RANO resect group.
     Neuro Oncol. 2024 Nov 4:noae231. doi: 10.1093.
     PubMed     Abstract available
     
     
     
219. MEHARI M, Sibih Y, Dada A, Chang SM, et al
     Enhancing neuro-oncology care through equity-driven applications of artificial intelligence.
     Neuro Oncol. 2024;26:1951-1963.
     PubMed     Abstract available
     
     
     
220. LIN S, Wang L, Han C, Dai Y, et al
     Targeting HTR2B suppresses nonfunctioning pituitary adenoma growth and sensitizes cabergoline treatment via inhibiting Galphaq/PLC/PKCgamma/STAT3 axis.
     Neuro Oncol. 2024;26:2010-2026.
     PubMed     Abstract available
     
     
     
221. TRINGALE KR, Scordo M, Yahalom J, White C, et al
     Outcomes and relapse patterns in primary central nervous system lymphoma: Longitudinal analysis of 559 patients diagnosed from 1983 to 2020.
     Neuro Oncol. 2024;26:2061-2073.
     PubMed     Abstract available
     
     
     October 2024
222. HOU J, Uejima T, Tanaka M, Son YL, et al
     EVA1-Antibody Drug Conjugate is a new therapeutic strategy for eliminating glioblastoma-initiating cells.
     Neuro Oncol. 2024 Oct 29:noae226. doi: 10.1093.
     PubMed     Abstract available
     
     
     
223. MOON HH, Park JE, Kim NY, Park SY, et al
     Prospective Longitudinal Analysis of Physiologic MRI-based Tumor Habitat Predicts Short-term Patient Outcomes in IDH-wildtype Glioblastoma.
     Neuro Oncol. 2024 Oct 25:noae227. doi: 10.1093.
     PubMed     Abstract available
     
     
     
224. GOTTARDO NG, Gajjar A
     Determining Risk Features for Medulloblastoma in the Molecular Era.
     Neuro Oncol. 2024 Oct 25:noae223. doi: 10.1093.
     PubMed    
     
     
     
225. GALLUS M, Young JS, Cook Quackenbush S, Khasraw M, et al
     Chimeric antigen receptor T-cell therapy in patients with malignant glioma-From neuroimmunology to clinical trial design considerations.
     Neuro Oncol. 2024 Oct 24:noae203. doi: 10.1093.
     PubMed     Abstract available
     
     
     
226. ZHU H, Cheng L, Liu D, Ma X, et al
     ROR1 facilitates glioblastoma growth via stabilizing GRB2 to promote c-Fos expression in glioma stem cells.
     Neuro Oncol. 2024 Oct 24:noae224. doi: 10.1093.
     PubMed     Abstract available
     
     
     
227. YANG R, Zhang G, Meng Z, Wang L, et al
     GDH1-catalytic glutaminolysis feedback activate EGFR/PI3K/AKT pathway and reprogram glioblastoma metabolism.
     Neuro Oncol. 2024 Oct 24:noae222. doi: 10.1093.
     PubMed     Abstract available
     
     
     
228. DU R, Zhang J, Lukas RV, Tripathi S, et al
     Is modulation of immune checkpoints on glioblastoma-infiltrating myeloid cells a viable therapeutic strategy?
     Neuro Oncol. 2024 Oct 19:noae193. doi: 10.1093.
     PubMed     Abstract available
     
     
     
229. DUERINCK J, Lescrauwaet L, Dirven I, Del'haye J, et al
     Intracranial administration of anti-PD-1 and anti-CTLA-4 immune checkpoint-blocking monoclonal antibodies in patients with recurrent high-grade glioma.
     Neuro Oncol. 2024 Oct 16:noae177. doi: 10.1093.
     PubMed     Abstract available
     
     
     
230. SCHREURS LD, Vom Stein AF, Junger ST, Timmer M, et al
     The Immune Landscape in Brain Metastasis.
     Neuro Oncol. 2024 Oct 15:noae219. doi: 10.1093.
     PubMed     Abstract available
     
     
     
231. GALLITTO M, Zhang X, De Los Santos G, Wei HJ, et al
     Targeted delivery of napabucasin with radiotherapy improves outcomes in diffuse midline glioma.
     Neuro Oncol. 2024 Oct 12:noae215. doi: 10.1093.
     PubMed     Abstract available
     
     
     
232. HONG JP, Choi RJ, Shim JK, Kim K, et al
     Synergistic combination of perphenazine and temozolomide suppresses patient-derived glioblastoma tumorspheres.
     Neuro Oncol. 2024 Oct 11:noae211. doi: 10.1093.
     PubMed     Abstract available
     
     
     
233. VAN DEN BENT MJ, Franceschi E, Touat M, French PJ, et al
     Updated EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection - Update 1.
     Neuro Oncol. 2024 Oct 10:noae213. doi: 10.1093.
     PubMed     Abstract available
     
     
     
234. VAN BREE N, Oppelt AS, Lindstrom S, Zhou L, et al
     Development of an orthotopic medulloblastoma zebrafish model for rapid drug testing.
     Neuro Oncol. 2024 Oct 9:noae210. doi: 10.1093.
     PubMed     Abstract available
     
     
     
235. ADIAMAH M, Poole B, Lindsey JC, Kohe S, et al
     MYC-dependent upregulation of the de novo serine and glycine synthesis pathway is a targetable metabolic vulnerability in group 3 medulloblastoma.
     Neuro Oncol. 2024 Oct 8:noae179. doi: 10.1093.
     PubMed     Abstract available
     
     
     
236. SCHWALBE EC, Lindsey JC, Danilenko M, Hill RM, et al
     Molecular and clinical heterogeneity within MYC-family amplified medulloblastoma is associated with survival outcomes: A multicenter cohort study.
     Neuro Oncol. 2024 Oct 8:noae178. doi: 10.1093.
     PubMed     Abstract available
     
     
     
237. KOH LWH, Pang QY, Novera W, Lim SW, et al
     EZH2 functional dichotomy in reactive oxygen species-stratified glioblastoma.
     Neuro Oncol. 2024 Oct 7:noae206. doi: 10.1093.
     PubMed     Abstract available
     
     
     
238. PRICE M, Ballard C, Benedetti J, Neff C, et al
     CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2017-2021.
     Neuro Oncol. 2024;26.
     PubMed     Abstract available
     
     
     
239. HUANG Y, Shan Y, Zhang W, Printzis C, et al
     Sex differences in the molecular profile of adult diffuse glioma are shaped by IDH status and tumor microenvironment.
     Neuro Oncol. 2024 Oct 5:noae207. doi: 10.1093.
     PubMed     Abstract available
     
     
     
240. TANG W, Dou H
     Letter to the editor on "The cochlear dose and the age at radiotherapy predict severe hearing loss after passive scattering proton therapy and cisplatin in children with medulloblastoma".
     Neuro Oncol. 2024 Oct 4:noae154. doi: 10.1093.
     PubMed    
     
     
     
241. BARTSCH R, Preusser M
     Trastuzumab deruxtecan - defining a novel systemic treatment standard for HER2-positive breast cancer brain metastases?
     Neuro Oncol. 2024 Oct 3:noae202. doi: 10.1093.
     PubMed    
     
     
     
242. HEGI ME, Oppong FB, Perry JR, Wick W, et al
     No benefit from TMZ treatment in glioblastoma with truly unmethylated MGMT promoter: Reanalysis of the CE.6 and the pooled Nordic/NOA-08 trials in elderly glioblastoma patients.
     Neuro Oncol. 2024;26:1867-1875.
     PubMed     Abstract available
     
     
     
243. GOLBOURN B, Ho B, Bondoc A, Luck A, et al
     A kinome drug screen identifies multi-TKI synergies and ERBB2 signaling as a therapeutic vulnerability in MYC/TYR subgroup atypical teratoid rhabdoid tumors.
     Neuro Oncol. 2024;26:1895-1911.
     PubMed     Abstract available
     
     
     
244. WILCOX JA, Chukwueke UN, Ahn MJ, Aizer AA, et al
     Leptomeningeal metastases from solid tumors: A Society for Neuro-Oncology and American Society of Clinical Oncology consensus review on clinical management and future directions.
     Neuro Oncol. 2024;26:1781-1804.
     PubMed     Abstract available
     
     
     
245. ZEYEN T, Bohm L, Paech D, Schafer N, et al
     Quantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with CCNU/TMZ.
     Neuro Oncol. 2024 Oct 1:noae205. doi: 10.1093.
     PubMed     Abstract available
     
     
     September 2024
246. EL SHAFIE RA, Bernhardt D, Welzel T, Schiele A, et al
     Stereotactic Radiosurgery for 1-10 Brain Metastases to avoid Whole-Brain Radiotherapy - Results of the CYBER-SPACE Randomized Phase 2 Trial.
     Neuro Oncol. 2024 Sep 28:noae201. doi: 10.1093.
     PubMed     Abstract available
     
     
     
247. NGUYEN MP, Morshed RA, Youngblood MW, Perlow HK, et al
     A targeted gene expression biomarker predicts clinic low-risk meningioma recurrence.
     Neuro Oncol. 2024 Sep 28:noae198. doi: 10.1093.
     PubMed     Abstract available
     
     
     
248. MASSIMINO M, Barretta F, Dossena C, Minasi S, et al
     Long-term outcome of the Milano-HART strategy for high-risk medulloblastoma, including the impact of molecular subtype.
     Neuro Oncol. 2024 Sep 27:noae189. doi: 10.1093.
     PubMed     Abstract available
     
     
     
249. WU J, Wishart BD, Cohen SE, Orme P, et al
     The Pediatric Physiatric Posterior Fossa Symptoms scale (3PFSs): Impairments and outcome in pediatric inpatient rehabilitation for posterior fossa brain tumors.
     Neuro Oncol. 2024 Sep 25:noae199. doi: 10.1093.
     PubMed     Abstract available
     
     
     
250. 
     Corrigendum to: Executive summary of the American Radium Society appropriate use criteria for brain metastases in epidermal growth factor receptor mutated-mutated and ALK-fusion non-small cell lung cancer.
     Neuro Oncol. 2024 Sep 21:noae197. doi: 10.1093.
     PubMed    
     
     
     
251. TOSEFSKY K, Yip S
     "Splice of Life: How RNA is Rewriting the Meningioma Story".
     Neuro Oncol. 2024 Sep 17:noae194. doi: 10.1093.
     PubMed    
     
     
     
252. 
     Erratum to: The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?
     Neuro Oncol. 2024 Sep 14:noae185. doi: 10.1093.
     PubMed    
     
     
     
253. SOUBERAN A, Jiguet-Jiglaire C, Toutain S, Morando P, et al
     Brain tumoroids: treatment prediction and drug development for brain tumors with fast, reproducible and easy-to-use personalized models.
     Neuro Oncol. 2024 Sep 10:noae184. doi: 10.1093.
     PubMed     Abstract available
     
     
     
254. REYES A, Stasenko A, Hopper A, Kohli JS, et al
     Cognitive phenotypes: Unraveling the heterogeneity in cognitive dysfunction among patients with primary brain tumors receiving radiotherapy.
     Neuro Oncol. 2024 Sep 9:noae183. doi: 10.1093.
     PubMed     Abstract available
     
     
     
255. AN Z, Fan QW, Wang L, Yoda H, et al
     EGFR and EGFRvIII coopt host defense pathways, promoting progression in glioblastoma.
     Neuro Oncol. 2024 Sep 9:noae182. doi: 10.1093.
     PubMed     Abstract available
     
     
     
256. SLOAN AE, Winter K, Gilbert MR, Aldape K, et al
     NRG-BN002: Phase I study of ipilimumab, nivolumab, and the combination in patients with newly diagnosed glioblastoma.
     Neuro Oncol. 2024;26:1628-1637.
     PubMed     Abstract available
     
     
     
257. NOH MH, Kang JM, Miller AA, Nguyen G, et al
     Targeting IGF2 to reprogram the tumor microenvironment for enhanced viro-immunotherapy.
     Neuro Oncol. 2024;26:1602-1616.
     PubMed     Abstract available
     
     
     
258. PIPER K, Kumar JI, Domino J, Tuchek C, et al
     Consensus review on strategies to improve delivery across the blood-brain barrier including focused ultrasound.
     Neuro Oncol. 2024;26:1545-1556.
     PubMed     Abstract available
     
     
     
259. LASTRA ROMERO A, Seitz T, Zisiadis GA, Jeffery H, et al
     EDA2R reflects the acute brain response to cranial irradiation in liquid biopsies.
     Neuro Oncol. 2024;26:1617-1627.
     PubMed     Abstract available
     
     
     
260. MASSAAD E, Smith WJ, Bradley J, Esposito E, et al
     Radical surgical resection with molecular margins is associated with improved survival in IDH wild-type glioblastoma.
     Neuro Oncol. 2024;26:1660-1669.
     PubMed     Abstract available
     
     
     
261. MCAFEE SS, Robinson G, Gajjar A, Phillips NS, et al
     Secondary cerebro-cerebellar and intra-cerebellar dysfunction in cerebellar mutism syndrome.
     Neuro Oncol. 2024;26:1700-1711.
     PubMed     Abstract available
     
     
     
262. 
     Corrigendum to: "Ras-mediated modulation of pyruvate dehydrogenase activity regulates mitochondrial reserve capacity and contributes to glioblastoma tumorigenesis".
     Neuro Oncol. 2024 Sep 2:noae156. doi: 10.1093.
     PubMed    
     
     
     August 2024
263. SAHM F, Aldape KD, Brastianos PK, Brat DJ, et al
     cIMPACT-NOW Update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas.
     Neuro Oncol. 2024 Aug 30:noae170. doi: 10.1093.
     PubMed     Abstract available
     
     
     
264. PERESLETE AM, Hughes ME, Martin AR, Files J, et al
     Analysis of HER2 expression changes from breast primary to brain metastases and the impact of HER2-low expression on overall survival.
     Neuro Oncol. 2024 Aug 30:noae163. doi: 10.1093.
     PubMed     Abstract available
     
     
     
265. MAHOOTIHA M, Tak D, Ye Z, Zapaishchykova A, et al
     Multimodal Deep Learning Improves Recurrence Risk Prediction in Pediatric Low-Grade Gliomas.
     Neuro Oncol. 2024 Aug 30:noae173. doi: 10.1093.
     PubMed     Abstract available
     
     
     
266. SANTOS L, Tomatis F, Ferreira HRS, Almeida SFF, et al
     ENPP1 induces blood-brain barrier dysfunction and promotes brain metastasis formation in HER2-positive breast cancer.
     Neuro Oncol. 2024 Aug 30:noae169. doi: 10.1093.
     PubMed     Abstract available
     
     
     
267. ALVAREZ-BRECKENRIDGE C, Brastianos P, Cahill D
     Thrombosis, brain metastasis formation, and the perivascular metastatic niche-novel insights from the tumor microvascular circulation.
     Neuro Oncol. 2024 Aug 29:noae168. doi: 10.1093.
     PubMed    
     
     
     
268. SHEN S, Cui Y, Li M, Yu K, et al
     TLR agonists promote formation of Tertiary Lymphoid Structure and improve anti-glioma immunity.
     Neuro Oncol. 2024 Aug 27:noae167. doi: 10.1093.
     PubMed     Abstract available
     
     
     
269. PARK JE, Oh JY, Park DH, Lee HS, et al
     Mapping Tumor Habitats in IDH-Wild Type Glioblastoma: Integrating MR Imaging, Pathologic, and RNA Data from Ivy Glioblastoma Atlas Project.
     Neuro Oncol. 2024 Aug 23:noae161. doi: 10.1093.
     PubMed     Abstract available
     
     
     
270. 
     Corrigendum to: LY6K promotes glioblastoma tumorigenicity via CAV-1-mediated ERK1/2 signaling enhancement.
     Neuro Oncol. 2024 Aug 21:noae151. doi: 10.1093.
     PubMed    
     
     
     
271. GHOSH HS, Patel RV, Woodward E, Greenwald NF, et al
     Contemporary Prognostic Signatures and Refined Risk Stratification of Gliomas: An Analysis of 4,400 Tumors.
     Neuro Oncol. 2024 Aug 21:noae164. doi: 10.1093.
     PubMed     Abstract available
     
     
     
272. GARCIA-MOURE M, Laspidea V, Gupta S, Gillard AG, et al
     The Emerging Field of Viroimmunotherapy for Pediatric Brain Tumors.
     Neuro Oncol. 2024 Aug 16:noae160. doi: 10.1093.
     PubMed     Abstract available
     
     
     
273. GUPTA P, Dang M, Oberai S, Migliozzi S, et al
     Immune landscape of isocitrate dehydrogenase-stratified primary and recurrent human gliomas.
     Neuro Oncol. 2024 Aug 10:noae139. doi: 10.1093.
     PubMed     Abstract available
     
     
     
274. MONTOYA M, Collins SA, Chuntova P, Patel TS, et al
     IRF8-driven reprogramming of the immune microenvironment enhances anti-tumor adaptive immunity and reduces immunosuppression in murine glioblastoma.
     Neuro Oncol. 2024 Aug 8:noae149. doi: 10.1093.
     PubMed     Abstract available
     
     
     
275. WELLER M, Albert NL, Galldiks N, Bink A, et al
     Targeted radionuclide therapy for gliomas: emerging clinical trial landscape.
     Neuro Oncol. 2024 Aug 6:noae125. doi: 10.1093.
     PubMed     Abstract available
     
     
     
276. KARSCHNIA P, Tonn JC
     Shaping the future of molecular neurosurgery: Toward epigenetic precision in surgical neuro-oncology?
     Neuro Oncol. 2024;26:1355-1356.
     PubMed    
     
     
     
277. BUDHIRAJA S, McManus G, Baisiwala S, Perrault EN, et al
     ARF4-mediated retrograde trafficking as a driver of chemoresistance in glioblastoma.
     Neuro Oncol. 2024;26:1421-1437.
     PubMed     Abstract available
     
     
     
278. ZHANG Y, Kang T, Wang Y, Song C, et al
     Low level of tumor necrosis factor alpha in tumor microenvironment maintains self-renewal of glioma stem cells by Vasorin-mediated glycolysis.
     Neuro Oncol. 2024 Aug 2:noae147. doi: 10.1093.
     PubMed     Abstract available
     
     
     
279. LECLAIR NK, Choudury A, Chen WC, Magill ST, et al
     RNA splicing as a biomarker and phenotypic driver of meningioma DNA methylation groups.
     Neuro Oncol. 2024 Aug 2:noae150. doi: 10.1093.
     PubMed     Abstract available
     
     
     July 2024
280. LIM-FAT MJ, Cotter JA, Touat M, Vogelzang J, et al
     A comparative analysis of IDH-mutant glioma in pediatric, young adult, and older adult patients.
     Neuro Oncol. 2024 Jul 31:noae142. doi: 10.1093.
     PubMed     Abstract available
     
     
     
281. LE RHUN E, Weller M
     Tools and toys beyond RANO 2.0: digital flipbooks to monitor brain tumor growth dynamics?
     Neuro Oncol. 2024 Jul 31:noae141. doi: 10.1093.
     PubMed    
     
     
     
282. SENER U, Sulman EP, Sarkaria JN
     Temozolomide Use in Elderly Patients with MGMT Promoter Unmethylated Glioblastoma: Is It Finally Time to Dismount a Dead Horse?
     Neuro Oncol. 2024 Jul 31:noae143. doi: 10.1093.
     PubMed    
     
     
     
283. KIM KS, Habashy K, Gould A, Zhao J, et al
     Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated BBB opening: A novel combinatorial immunotherapy regimen for gliomas.
     Neuro Oncol. 2024 Jul 19:noae135. doi: 10.1093.
     PubMed     Abstract available
     
     
     
284. CHAN A, Zhang K, Martin G, Bano S, et al
     Maternal obesogenic diet operates at the tumor cell of origin to increase incidence and decrease latency of Neurofibromatosis Type 1 optic pathway glioma.
     Neuro Oncol. 2024 Jul 18:noae136. doi: 10.1093.
     PubMed     Abstract available
     
     
     
285. KETKAR M, Desai S, Rana P, Thorat R, et al
     Inhibition of PERK mediated UPR acts as a switch for reversal of residual senescence and as senolytic therapy in glioblastoma.
     Neuro Oncol. 2024 Jul 18:noae134. doi: 10.1093.
     PubMed     Abstract available
     
     
     
286. 
     Erratum to: QOL-14. EPILEPTIC SEIZURES, ANTI-SEIZURE MEDICATIONS, AND NEUROCOGNITION IN SURVIVORS OF PEDIATRIC BRAIN TUMORS.
     Neuro Oncol. 2024 Jul 17:noae129. doi: 10.1093.
     PubMed    
     
     
     
287. LUO X, Yang Y, Yin S, Li H, et al
     Automated segmentation of brain metastases with deep learning: a multi-center, randomized crossover, multi-reader evaluation study.
     Neuro Oncol. 2024 Jul 11:noae113. doi: 10.1093.
     PubMed     Abstract available
     
     
     
288. FIGG J, Chen D, Falceto Font L, Flores C, et al
     In Vivo Mouse Models for Adult Brain Tumors: Exploring Tumorigenesis and Advancing Immunotherapy Development.
     Neuro Oncol. 2024 Jul 11:noae131. doi: 10.1093.
     PubMed     Abstract available
     
     
     
289. HOU AJ, Shih RM, Uy BR, Shafer A, et al
     IL-13Ralpha2/TGF-beta bispecific CAR-T cells counter TGF-beta-mediated immune suppression and potentiate anti-tumor responses in glioblastoma.
     Neuro Oncol. 2024 Jul 10:noae126. doi: 10.1093.
     PubMed     Abstract available
     
     
     
290. GALLDIKS N, Lohmann P, Friedrich M, Werner JM, et al
     PET imaging of gliomas: Status quo and quo vadis?
     Neuro Oncol. 2024 Jul 6:noae078. doi: 10.1093.
     PubMed     Abstract available
     
     
     
291. LI B, Zhao S, Li S, Li C, et al
     Novel molecular subtypes of intracranial germ cell tumors expand therapeutic opportunities.
     Neuro Oncol. 2024;26:1335-1351.
     PubMed     Abstract available
     
     
     
292. ROZENBLUM L, Houillier C, Baptiste A, Soussain C, et al
     Interim FDG-PET improves treatment failure prediction in primary central nervous system lymphoma: An LOC network prospective multicentric study.
     Neuro Oncol. 2024;26:1292-1301.
     PubMed     Abstract available
     
     
     
293. PAPINI C, Mirzaei S S, Xing M, Tonning Olsson I, et al
     Neurocognitive outcomes and functional independence in adult survivors of childhood medulloblastoma diagnosed over three decades.
     Neuro Oncol. 2024 Jul 4:noae119. doi: 10.1093.
     PubMed     Abstract available
     
     
     
294. BARTSCH R, Berghoff AS, Furtner J, Marhold M, et al
     FINAL outcome ANALYSIS FROM THE PHASE II TUXEDO-1 TRIAL OF TRASTUZUMAB-DERUXTECAN IN HER2-positive breast cancer PATIENTS WITH active brain metastases.
     Neuro Oncol. 2024 Jul 4:noae123. doi: 10.1093.
     PubMed     Abstract available
     
     
     
295. MARQUEZ-RODAS I, Alvarez A, Arance A, Valduvieco I, et al
     Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study).
     Neuro Oncol. 2024 Jul 1:noae116. doi: 10.1093.
     PubMed     Abstract available
     
     
     June 2024
296. KINSLOW CJ, Roy S, Iwamoto FM, Brown PD, et al
     The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH-wildtype and -mutant lower grade gliomas.
     Neuro Oncol. 2024 Jun 29:noae102. doi: 10.1093.
     PubMed     Abstract available
     
     
     
297. LIU SJ, Raleigh DR, de Groot JF
     Proteasome inhibition for glioblastoma: lessons learned and new opportunities.
     Neuro Oncol. 2024 Jun 27:noae118. doi: 10.1093.
     PubMed    
     
     
     
298. SONKSEN M, Obrecht-Sturm D, Hernaiz Driever P, Sauerbrey A, et al
     Medulloblastoma in children with Fanconi anemia: Association with FA-D1/FA-N, SHH type and poor survival independent of treatment strategies.
     Neuro Oncol. 2024 Jun 26:noae111. doi: 10.1093.
     PubMed     Abstract available
     
     
     
299. NAKASE T, Guerra GA, Ostrom QT, Ge T, et al
     Genome-wide Polygenic Risk Scores Predict Risk of Glioma and Molecular Subtypes.
     Neuro Oncol. 2024 Jun 25:noae112. doi: 10.1093.
     PubMed     Abstract available
     
     
     
300. ABU-ARJA MH, Brown AL, Su JM, Okcu MF, et al
     The cochlear dose and the age at radiotherapy predict severe hearing loss after passive scattering proton therapy and cisplatin in children with medulloblastoma.
     Neuro Oncol. 2024 Jun 25:noae114. doi: 10.1093.
     PubMed     Abstract available
     
     
     
301. VAN DEN BENT MJ, French PJ, Brat D, Tonn JC, et al
     The biological significance of tumor grade, age, enhancement and extent of resection in IDH mutant gliomas: how should they inform treatment decision in the era of IDH inhibitors? Invited review.
     Neuro Oncol. 2024 Jun 24:noae107. doi: 10.1093.
     PubMed     Abstract available
     
     
     
302. SEGURA-COLLAR B, Gargini R
     Sex differences in glioblastoma based on tumor subtypes.
     Neuro Oncol. 2024 Jun 17:noae089. doi: 10.1093.
     PubMed    
     
     
     
303. OFFI M, Gabriele L, Romagnoli G, Lauretti L, et al
     The Sybil prophecy: Searching for predictors of response to bevacizumab in glioblastoma.
     Neuro Oncol. 2024 Jun 17:noae088. doi: 10.1093.
     PubMed    
     
     
     
304. RENOULT O, Laurent-Blond M, Awada H, Oliver L, et al
     Metabolic Profiling of Glioblastoma Stem Cells Reveals Pyruvate Carboxylase as a Critical Survival Factor and Potential Therapeutic Target.
     Neuro Oncol. 2024 Jun 13:noae106. doi: 10.1093.
     PubMed     Abstract available
     
     
     
305. ZHOU L, van Bree N, Boutin L, Ryu J, et al
     High-throughput neural stem cell-based drug screening identifies S6K1 inhibition as a selective vulnerability in SHH-medulloblastoma.
     Neuro Oncol. 2024 Jun 11:noae104. doi: 10.1093.
     PubMed     Abstract available
     
     
     
306. DOBBER L, Geurts M, van den Bent MJ
     Tumor growth in recurrent glioblastoma-RANO: when to plan the baseline scan?
     Neuro Oncol. 2024 Jun 10:noae095. doi: 10.1093.
     PubMed    
     
     
     
307. MYNAREK M, Rossius A, Guiard A, Ottensmeier H, et al
     Risk factors for domain-specific neurocognitive outcome in pediatric survivors of a brain tumor in the posterior fossa - Results of the HIT 2000 trial.
     Neuro Oncol. 2024 Jun 5:noae092. doi: 10.1093.
     PubMed     Abstract available
     
     
     
308. ROESLER J, Spitzer D, Jia X, Aasen SN, et al
     Disturbance in cerebral blood microcirculation and hypoxic-ischemic microenvironment are associated with the development of brain metastasis.
     Neuro Oncol. 2024 Jun 4:noae094. doi: 10.1093.
     PubMed     Abstract available
     
     
     
309. GROGAN PT, Vogelbaum MA
     Diffuse Midline (H3 K27M-Mutant) Glioma in Adults - Resection Fails to Matter.
     Neuro Oncol. 2024 Jun 3:noae099. doi: 10.1093.
     PubMed    
     
     
     
310. LITA A, Sjoberg J, Pacioianu D, Siminea N, et al
     Raman-based machine learning platform reveals unique metabolic differences between IDHmut and IDHwt glioma.
     Neuro Oncol. 2024 Jun 3:noae101. doi: 10.1093.
     PubMed     Abstract available
     
     
     
311. NAYAK L, Bettegowda C, Scherer F, Galldiks N, et al
     Liquid biopsy for improving diagnosis and monitoring of CNS lymphomas: A RANO review.
     Neuro Oncol. 2024;26:993-1011.
     PubMed     Abstract available
     
     
     
312. GALBRAITH K, Garcia M, Wei S, Chen A, et al
     Prognostic value of DNA methylation subclassification, aneuploidy, and CDKN2A/B homozygous deletion in predicting clinical outcome of IDH mutant astrocytomas.
     Neuro Oncol. 2024;26:1042-1051.
     PubMed     Abstract available
     
     
     
313. HASKELL-MENDOZA AP, Reason EH, Gonzalez AT, Jackson JD, et al
     Automated segmentation of ablated lesions using deep convolutional neural networks: A basis for response assessment following laser interstitial thermal therapy.
     Neuro Oncol. 2024;26:1152-1162.
     PubMed     Abstract available
     
     
     
314. LANG F, Cornwell JA, Kaur K, Elmogazy O, et al
     Abrogation of the G2/M checkpoint as a chemosensitization approach for alkylating agents.
     Neuro Oncol. 2024;26:1083-1096.
     PubMed     Abstract available
     
     
     
315. PARK YW, Jang G, Kim SB, Choi K, et al
     Leptomeningeal Metastases in IDH-wildtype Glioblastomas Revisited: Comprehensive Analysis of Incidence, Risk Factors, and Prognosis Based on Post-contrast FLAIR.
     Neuro Oncol. 2024 Jun 1:noae091. doi: 10.1093.
     PubMed     Abstract available
     
     
     May 2024
316. BUCHNER JA, Kofler F, Mayinger M, Christ SM, et al
     Radiomics-based prediction of local control in patients with brain metastases following postoperative stereotactic radiotherapy.
     Neuro Oncol. 2024 May 30:noae098. doi: 10.1093.
     PubMed     Abstract available
     
     
     
317. CHO NS, Le VL, Sanvito F, Oshima S, et al
     Digital "flipbooks" for enhanced visual assessment of simple and complex brain tumors.
     Neuro Oncol. 2024 May 29:noae097. doi: 10.1093.
     PubMed     Abstract available
     
     
     
318. ZHANG Y, Hudson K, Abounader R
     Unraveling the hypoxic puzzle: LncRNA LUCAT1 drives glioblastoma in cooperation with HIF1?.
     Neuro Oncol. 2024 May 21:noae096. doi: 10.1093.
     PubMed    
     
     
     
319. FAMILIAR AM, Fathi Kazerooni A, Vossough A, Ware JB, et al
     Towards Consistency in Pediatric Brain Tumor Measurements: Challenges, Solutions, and the Role of AI-Based Segmentation.
     Neuro Oncol. 2024 May 21:noae093. doi: 10.1093.
     PubMed     Abstract available
     
     
     
320. O'HARE P, Cooney T, de Blank P, Gutmann DH, et al
     Resistance, rebound, and recurrence regrowth patterns in pediatric low-grade glioma treated by MAPK inhibition: A modified Delphi approach to build international consensus-based definitions-International Pediatric Low-Grade Glioma Coalition.
     Neuro Oncol. 2024 May 14:noae074. doi: 10.1093.
     PubMed     Abstract available
     
     
     
321. LEON BE, Bayik D
     A triad between sex, necrosis, and inflammation shapes glioblastoma outcomes.
     Neuro Oncol. 2024 May 14:noae086. doi: 10.1093.
     PubMed    
     
     
     
322. LI M, Zhang Z, He L, Wang X, et al
     SMYD2 induced PGC1alpha methylation promotes stemness maintenance of glioblastoma stem cells.
     Neuro Oncol. 2024 May 9:noae090. doi: 10.1093.
     PubMed     Abstract available
     
     
     
323. NUSSBAUMER G, Benesch M, Grabovska Y, Mackay A, et al
     Gliomatosis cerebri in children: A poor prognostic phenotype of diffuse gliomas with a distinct molecular profile.
     Neuro Oncol. 2024 May 8:noae080. doi: 10.1093.
     PubMed     Abstract available
     
     
     
324. 
     Corrigendum to: The surgical management of diffuse gliomas: Current state of neurosurgical management and future directions.
     Neuro Oncol. 2024 May 7:noae083. doi: 10.1093.
     PubMed    
     
     
     
325. PRICE M, Neff C, Nagarajan N, Kruchko C, et al
     CBTRUS Statistical Report: American Brain Tumor Association & NCI Neuro-Oncology Branch Adolescent and Young Adult Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016-2020.
     Neuro Oncol. 2024;26.
     PubMed     Abstract available
     
     
     
326. MAIR MJ, Tabouret E, Johnson DR, Sulman EP, et al
     Radioligand therapies in meningioma - evidence and future directions.
     Neuro Oncol. 2024 May 4:noae069. doi: 10.1093.
     PubMed     Abstract available
     
     
     
327. POLLEY MC, Schwartz D, Karrison T, Dignam JJ, et al
     Leveraging external control data in the design and analysis of neuro-oncology trials: Pearls and perils.
     Neuro Oncol. 2024;26:796-810.
     PubMed     Abstract available
     
     
     
328. WAGNER A, Brielmaier MC, Kampf C, Baumgart L, et al
     Fluorescein-stained confocal laser endomicroscopy versus conventional frozen section for intraoperative histopathological assessment of intracranial tumors.
     Neuro Oncol. 2024;26:922-932.
     PubMed     Abstract available
     
     
     
329. DOTTERMUSCH M, Biabani A, Lempertz T, Schumann Y, et al
     Integrated proteomics spotlight the proteasome as a therapeutic vulnerability in embryonal tumors with multilayered rosettes.
     Neuro Oncol. 2024;26:935-949.
     PubMed     Abstract available
     
     
     
330. SURESH H, Morgan BR, Mithani K, Warsi NM, et al
     Postoperative cerebellar mutism syndrome is an acquired autism-like network disturbance.
     Neuro Oncol. 2024;26:950-964.
     PubMed     Abstract available
     
     
     
331. CHERNG HR, Sun K, Bentzen S, Armstrong TS, et al
     Evaluating the heterogeneity of hippocampal avoidant whole brain radiotherapy treatment effect: A secondary analysis of NRG CC001.
     Neuro Oncol. 2024;26:911-921.
     PubMed     Abstract available
     
     
     
332. WANG JZ, Landry AP, Raleigh DR, Sahm F, et al
     Meningioma: International Consortium on Meningiomas (ICOM) consensus review on scientific advances & treatment paradigms for clinicians, researchers, and patients.
     Neuro Oncol. 2024 May 2:noae082. doi: 10.1093.
     PubMed     Abstract available
     
     
     
333. HENDRIKSEN JD, Locallo A, Maarup S, Debnath O, et al
     Immunotherapy drives mesenchymal tumour cell state shift and TME immune response in glioblastoma patients.
     Neuro Oncol. 2024 May 2:noae085. doi: 10.1093.
     PubMed     Abstract available
     
     
     April 2024
334. MURPHY ES, Yang K, Suh JH, Yu JS, et al
     Phase I trial of dose escalation for preoperative stereotactic radiosurgery for patients with large brain metastases.
     Neuro Oncol. 2024 Apr 24:noae076. doi: 10.1093.
     PubMed     Abstract available
     
     
     
335. PACKER RJ
     Very long-term outcomes of pediatric patients treated for optic pathway gliomas: A longitudinal cohort study.
     Neuro Oncol. 2024 Apr 17:noae079. doi: 10.1093.
     PubMed    
     
     
     
336. ANASTASAKI C, Chatterjee J, Koleske JP, Gao Y, et al
     NF1 mutation-driven neuronal hyperexcitability sets a threshold for tumorigenesis and therapeutic targeting of murine optic glioma.
     Neuro Oncol. 2024 Apr 12:noae054. doi: 10.1093.
     PubMed     Abstract available
     
     
     
337. TOHIDINEZHAD F, Zegers CML, Vaassen F, Dijkstra J, et al
     Predicting the risk of neurocognitive decline after brain irradiation in adult patients with a primary brain tumor.
     Neuro Oncol. 2024 Apr 10:noae035. doi: 10.1093.
     PubMed     Abstract available
     
     
     
338. GEURTS M, Preusser M
     Locoregional delivery of CAR-T cells - breaking the spell in glioblastoma?
     Neuro Oncol. 2024 Apr 9:noae063. doi: 10.1093.
     PubMed    
     
     
     
339. ARRILLAGA-ROMANY I, Miller JJ
     Demonstrated efficacy and mechanisms of sensitivity of ONC201: H3K27M-mutant diffuse midline glioma in the spotlight.
     Neuro Oncol. 2024 Apr 8:noae051. doi: 10.1093.
     PubMed    
     
     
     
340. OBRECHT-STURM D, Schomig L, Mynarek M, Bison B, et al
     Treatment response as surrogate to predict risk for disease progression in pediatric medulloblastoma with persistent MRI lesions after first-line treatment.
     Neuro Oncol. 2024 Apr 5:noae071. doi: 10.1093.
     PubMed     Abstract available
     
     
     
341. CIOFFI G, Waite KA, Price M, Neff C, et al
     The impact of COVID-19 on 2020 monthly incidence trends of primary brain and other CNS tumors.
     Neuro Oncol. 2024;26:764-774.
     PubMed     Abstract available
     
     
     
342. APPIN CL, Hong C, Suwala AK, Hilz S, et al
     Whole tumor analysis reveals early origin of the TERT promoter mutation and intercellular heterogeneity in TERT expression.
     Neuro Oncol. 2024;26:640-652.
     PubMed     Abstract available
     
     
     
343. DUMOT C, Mantziaris G, Dayawansa S, Peker S, et al
     Stereotactic radiosurgery for nonfunctioning pituitary tumor: A multicenter study of new pituitary hormone deficiency.
     Neuro Oncol. 2024;26:715-723.
     PubMed     Abstract available
     
     
     
344. BUDHU JA, Chukwueke UN, Jackson S, Lee EQ, et al
     Defining interventions and metrics to improve diversity in CNS clinical trial participation: A SNO and RANO effort.
     Neuro Oncol. 2024;26:596-608.
     PubMed     Abstract available
     
     
     
345. BROMBERG JEC, Issa S, van der Holt B, van der Meulen M, et al
     Survival, neurocognitive function, and health-related quality of life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study.
     Neuro Oncol. 2024;26:724-734.
     PubMed     Abstract available
     
     
     
346. RICKLEFS FL, Wollmann K, Salviano-Silva A, Drexler R, et al
     Circulating extracellular vesicles as biomarker for diagnosis, prognosis and monitoring in glioblastoma patients.
     Neuro Oncol. 2024 Apr 3:noae068. doi: 10.1093.
     PubMed     Abstract available
     
     
     March 2024
347. XIE H, Jiang Y, Xiang Y, Wu B, et al
     Super-enhancer-driven LIF promotes the mesenchymal transition in glioblastoma by activating ITGB2 signaling feedback in microglia.
     Neuro Oncol. 2024 Mar 30:noae065. doi: 10.1093.
     PubMed     Abstract available
     
     
     
348. DE LA NAVA D, Ausejo-Mauleon I, Laspidea V, Gonzalez-Huarriz M, et al
     The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models.
     Neuro Oncol. 2024 Mar 30:noae066. doi: 10.1093.
     PubMed     Abstract available
     
     
     
349. IVANIDZE J, Chang SJ, Haghdel A, Kim JT, et al
     [Ga68] DOTATATE PET/MRI-Guided Radiosurgical Treatment Planning and Response Assessment in Meningiomas.
     Neuro Oncol. 2024 Mar 30:noae067. doi: 10.1093.
     PubMed     Abstract available
     
     
     
350. MCCORD M, Jamshidi P
     Targeting the cell cycle to enhance chemotherapy efficacy in glioblastoma.
     Neuro Oncol. 2024 Mar 22:noae062. doi: 10.1093.
     PubMed    
     
     
     
351. RAHMAN R, Shi DD, Reitman ZJ, Hamerlik P, et al
     DNA damage response in brain tumors: A Society for Neuro-Oncology consensus review on mechanisms and translational efforts in neuro-oncology.
     Neuro Oncol. 2024 Mar 22:noae072. doi: 10.1093.
     PubMed     Abstract available
     
     
     
352. RYBA A, Ozdemir Z, Nissimov N, Honikl L, et al
     Insights from a Multicenter Study on Adult H3 K27M-Mutated Glioma: Surgical Resection's Limited Influence on Overall Survival, ATRX as Molecular Prognosticator.
     Neuro Oncol. 2024 Mar 20:noae061. doi: 10.1093.
     PubMed     Abstract available
     
     
     
353. ALVAREZ-VAZQUEZ A, San-Segundo L, Cervero-Garcia P, Flores-Hernandez R, et al
     EGFR amplification and EGFRvIII predict and participate in TAT-Cx43266-283 antitumor response in preclinical glioblastoma models.
     Neuro Oncol. 2024 Mar 20:noae060. doi: 10.1093.
     PubMed     Abstract available
     
     
     
354. 
     Corrigendum to: Chaetocin-mediated SUV39H1 inhibition targets stemness and oncogenic networks of diffuse midline gliomas and synergizes with ONC201.
     Neuro Oncol. 2024 Mar 20:noae055. doi: 10.1093.
     PubMed    
     
     
     
355. ROTH P, Gorlia T, Reijneveld JC, de Vos F, et al
     Marizomib for patients with newly diagnosed glioblastoma: a randomized phase 3 trial.
     Neuro Oncol. 2024 Mar 19:noae053. doi: 10.1093.
     PubMed     Abstract available
     
     
     
356. LECHPAMMER M
     Can confocal laser endomicroscopy replace frozen section in diagnosis of brain tumors? A definite maybe.
     Neuro Oncol. 2024 Mar 15:noae042. doi: 10.1093.
     PubMed    
     
     
     
357. LAWLER S
     Identification of transcriptomic signatures associated with glioblastoma recurrence.
     Neuro Oncol. 2024 Mar 12:noae044. doi: 10.1093.
     PubMed    
     
     
     
358. STEVERS NO, Costello JF
     Telomeres in glioma: Maintenance mechanisms to therapeutic potential.
     Neuro Oncol. 2024 Mar 11:noae052. doi: 10.1093.
     PubMed    
     
     
     
359. GALLDIKS N, Kaufmann TJ, Vollmuth P, Lohmann P, et al
     Challenges, Limitations and Pitfalls of PET and Advanced MRI in Patients with Brain Tumors - A Report of the PET/RANO Group.
     Neuro Oncol. 2024 Mar 11:noae049. doi: 10.1093.
     PubMed     Abstract available
     
     
     
360. MOREIRA DC, Qaddoumi I, Spiller S, Bouldin TW, et al
     Comprehensive analysis of MYB/MYBL1-altered pediatric-type diffuse low-grade glioma.
     Neuro Oncol. 2024 Mar 11:noae048. doi: 10.1093.
     PubMed     Abstract available
     
     
     
361. MORIN A, Allodji R, Kariyawasam D, Touraine P, et al
     Very long-term outcomes of pediatric patients treated for optic pathway gliomas: A longitudinal cohort study.
     Neuro Oncol. 2024 Mar 11:noae045. doi: 10.1093.
     PubMed     Abstract available
     
     
     
362. NAGPAL S, Milano MT, Chiang VL, Soltys SG, et al
     Executive Summary of the American Radium Society Appropriate Use Criteria for Brain Metastases in EGFR-mutated and ALK-fusion Non-Small Cell Lung Cancer.
     Neuro Oncol. 2024 Mar 9:noae041. doi: 10.1093.
     PubMed     Abstract available
     
     
     
363. HUANG H, Shah H, Hao J, Lin J, et al
     LncRNA LUCAT1 Promotes Glioblastoma Progression by Enhancing HIF1alpha Activity.
     Neuro Oncol. 2024 Mar 8:noae036. doi: 10.1093.
     PubMed     Abstract available
     
     
     
364. TABOURET E, Furtner J, Graillon T, Silvani A, et al
     3D volume growth rate evaluation in the EORTC-BTG-1320 clinical trial for recurrent WHO grade 2 and 3 meningiomas.
     Neuro Oncol. 2024 Mar 7:noae037. doi: 10.1093.
     PubMed     Abstract available
     
     
     
365. ARRILLAGA-ROMANY I, Lassman A, McGovern SL, Mueller S, et al
     ACTION: A randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma.
     Neuro Oncol. 2024 Mar 6:noae031. doi: 10.1093.
     PubMed     Abstract available
     
     
     
366. LEE MD, Jain R
     Harnessing Generative AI for Glioma Diagnosis: A Step Forward in Neuro-Oncologic Imaging.
     Neuro Oncol. 2024 Mar 5:noae043. doi: 10.1093.
     PubMed    
     
     
     
367. SHIXUE Y, Qi Z, Dongyuan S, Xiaoteng C, et al
     HIF1alpha/ATF3 partake PGK1 K191/K192 succinylation by modulating P4HA1/succinate signaling in glioblastoma.
     Neuro Oncol. 2024 Mar 5:noae040. doi: 10.1093.
     PubMed     Abstract available
     
     
     
368. TSENG CL, Zeng KL, Mellon EA, Soltys SG, et al
     Evolving concepts in margin strategies and adaptive radiotherapy for glioblastoma: A new future is on the horizon.
     Neuro Oncol. 2024;26.
     PubMed     Abstract available
     
     
     
369. PALMER JD, Perlow HK, Lehrer EJ, Wardak Z, et al
     Novel radiotherapeutic strategies in the management of brain metastases: Challenging the dogma.
     Neuro Oncol. 2024;26.
     PubMed     Abstract available
     
     
     
370. KOTECHA R, La Rosa A, Mehta MP
     How proton therapy fits into the management of adult intracranial tumors.
     Neuro Oncol. 2024;26.
     PubMed     Abstract available
     
     
     
371. BREEN WG, Aryal MP, Cao Y, Kim MM, et al
     Integrating multi-modal imaging in radiation treatments for glioblastoma.
     Neuro Oncol. 2024;26.
     PubMed     Abstract available
     
     
     
372. MAYO ZS, Billena C, Suh JH, Lo SS, et al
     The dilemma of radiation necrosis from diagnosis to treatment in the management of brain metastases.
     Neuro Oncol. 2024;26.
     PubMed     Abstract available
     
     
     
373. SAHGAL A, Chang S
     Pushing the boundaries of radiation technology for the management of central nervous system tumors.
     Neuro Oncol. 2024;26.
     PubMed    
     
     
     
374. COY S, Lee JS, Chan SJ, Woo T, et al
     Systematic characterization of antibody-drug conjugate targets in central nervous system tumors.
     Neuro Oncol. 2024;26:458-472.
     PubMed     Abstract available
     
     
     February 2024
375. KIDWELL RL, Aghi MK
     Lymphatic endothelial-like cells in the glioblastoma tumor niche drive metabolic alterations that promote stem cell proliferation and survival.
     Neuro Oncol. 2024 Feb 28:noae020. doi: 10.1093.
     PubMed    
     
     
     
376. KE C, Huang B, Xiang J, Liang J, et al
     Secreted Clusterin Inhibits Tumorigenesis by Modulating Tumor Cell and Macrophage in Human Meningioma.
     Neuro Oncol. 2024 Feb 28:noae034. doi: 10.1093.
     PubMed     Abstract available
     
     
     
377. HILLER-VALLINA S, Mondejar-Ruescas L, Caamano-Moreno M, Comitre-Mariano B, et al
     Sexual-biased necroinflammation is revealed as a predictor of bevacizumab benefit in Glioblastoma.
     Neuro Oncol. 2024 Feb 27:noae033. doi: 10.1093.
     PubMed     Abstract available
     
     
     
378. ODIA Y, Koschmann C, Vitanza NA, de Blank P, et al
     Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3K27M-mutant glioma.
     Neuro Oncol. 2024 Feb 24:noae001. doi: 10.1093.
     PubMed     Abstract available
     
     
     
379. 
     Corrigendum to: Consensus framework for conducting phase I/II clinical trials for children, adolescents, and young adults with pediatric low-grade glioma: Guidelines established by the International Pediatric Low-Grade Glioma Coalition Clinical Trial
     Neuro Oncol. 2024 Feb 23:noae030. doi: 10.1093.
     PubMed    
     
     
     
380. SLOAN AR, Silver DJ, Kint S, Gallo M, et al
     Cancer stem cell hypothesis 2.0 in glioblastoma: Where are we now and where are we going?
     Neuro Oncol. 2024 Feb 23:noae011. doi: 10.1093.
     PubMed     Abstract available
     
     
     
381. ODIA Y, Hall MD, Cloughesy TF, Wen PY, et al
     Selective DRD2 Antagonist and ClpP Agonist ONC201 in a Recurrent Non-midline H3 K27M-mutant Glioma Cohort.
     Neuro Oncol. 2024 Feb 22:noae021. doi: 10.1093.
     PubMed     Abstract available
     
     
     
382. 
     Corrigendum to: Consensus framework for conducting phase I/II clinical trials for children, adolescents, and young adults with pediatric low-grade glioma: Guidelines established by the International Pediatric Low-Grade Glioma Coalition Clinical Trial
     Neuro Oncol. 2024 Feb 16:noae024. doi: 10.1093.
     PubMed    
     
     
     
383. CHENG HS, Chong YK, Lim EKY, Lee XY, et al
     Dual p38MAPK and MEK inhibition disrupts adaptive chemoresistance in mesenchymal glioblastoma to temozolomide.
     Neuro Oncol. 2024 Feb 16:noae028. doi: 10.1093.
     PubMed     Abstract available
     
     
     
384. SILVESTRI VL, Tran AD, Chung M, Chung N, et al
     Distinct uptake and elimination profiles for trastuzumab, human IgG and biocytin-TMR in experimental HER2+ brain metastases of breast cancer.
     Neuro Oncol. 2024 Feb 13:noae025. doi: 10.1093.
     PubMed     Abstract available
     
     
     
385. MOREIRA DC, Bouffet E, Qaddoumi I
     The greatest challenge for pediatric low-grade glioma.
     Neuro Oncol. 2024 Feb 10:noae004. doi: 10.1093.
     PubMed    
     
     
     
386. PRINCE EW, Apps JR, Jeang J, Chee K, et al
     Unraveling the Complexity of the Senescence-Associated Secretory Phenotype in Adamantinomatous Craniopharyngioma Using Multi-Modal Machine Learning Analysis.
     Neuro Oncol. 2024 Feb 9:noae015. doi: 10.1093.
     PubMed     Abstract available
     
     
     
387. 
     Expression of Concern: microRNA-7 upregulates death receptor 5 and primes resistant brain tumors to caspase-mediated apoptosis.
     Neuro Oncol. 2024 Feb 9:noae026. doi: 10.1093.
     PubMed    
     
     
     
388. LAUER EM, Riegler E, Mutter JA, Alig SK, et al
     Improved early outcome prediction by MRI-based 3D tumor volume assessment in patients with CNS lymphomas.
     Neuro Oncol. 2024;26:374-386.
     PubMed     Abstract available
     
     
     January 2024
389. NELLAN A, Jackson S
     Targeted therapy done right: direct SHH Inhibition for SHH medulloblastoma.
     Neuro Oncol. 2024 Jan 30:noae018. doi: 10.1093.
     PubMed    
     
     
     
390. GHOSH S, Rothlin CV
     TREM2 function in glioblastoma immune microenvironment: can we distinguish reality from illusion?
     Neuro Oncol. 2024 Jan 30:noae019. doi: 10.1093.
     PubMed    
     
     
     
391. CHELLIAH A, Wood DA, Canas LS, Shuaib H, et al
     Glioblastoma and Radiotherapy: a multi-center AI study for Survival Predictions from MRI (GRASP study).
     Neuro Oncol. 2024 Jan 29:noae017. doi: 10.1093.
     PubMed     Abstract available
     
     
     
392. WAITKUS MS, Erman EN, Reitman ZJ, Ashley DM, et al
     Mechanisms of telomere maintenance and associated therapeutic vulnerabilities in malignant gliomas.
     Neuro Oncol. 2024 Jan 29:noae016. doi: 10.1093.
     PubMed     Abstract available
     
     
     
393. WANG S, Qi Y, Zhao R, Pan Z, et al
     Copy number gain of FAM131B-AS2 promotes the progression of glioblastoma by mitigating replication stress.
     Neuro Oncol. 2024 Jan 29:noae014. doi: 10.1093.
     PubMed     Abstract available
     
     
     
394. MACK SC, Bertrand KC
     Understanding the Mechanisms of Diffuse Midline Glioma Cell Migration Towards Therapeutic Targeting.
     Neuro Oncol. 2024 Jan 27:noad263. doi: 10.1093.
     PubMed    
     
     
     
395. DANKNER M, Maritan SM, Priego N, Kruck G, et al
     Invasive growth of brain metastases is linked to CHI3L1 release from pSTAT3-positive astrocytes.
     Neuro Oncol. 2024 Jan 25:noae013. doi: 10.1093.
     PubMed     Abstract available
     
     
     
396. RANDALL J, Sachdev S
     A valuable glioblastoma prognostic maker driven by radiosensitivity.
     Neuro Oncol. 2024 Jan 23:noad266. doi: 10.1093.
     PubMed    
     
     
     
397. MOON HH, Jeong J, Park JE, Kim N, et al
     Generative AI in glioma: ensuring diversity in training image phenotypes to improve diagnostic performance for IDH mutation prediction.
     Neuro Oncol. 2024 Jan 22:noae012. doi: 10.1093.
     PubMed     Abstract available
     
     
     
398. SUN Y, Mu G, Xue Z, Wang S, et al
     Polyunsaturated fatty acid-binding protein FABP7, an attractive metabolic target for inhibition of glioblastoma stem cells.
     Neuro Oncol. 2024 Jan 19:noad238. doi: 10.1093.
     PubMed    
     
     
     
399. LIU RZ, Choi WS, Godbout R
     Nuclear translocation matters: Role of FABP7 in driving glioblastoma stemness and invasion: Reply to Mu et al.
     Neuro Oncol. 2024 Jan 19:noad239. doi: 10.1093.
     PubMed    
     
     
     
400. ZIEGLER DS, Lehmann R, Eisenstat DD
     A paradigm shift in how we treat pediatric low grade glioma - targeting the molecular drivers.
     Neuro Oncol. 2024 Jan 19:noae008. doi: 10.1093.
     PubMed    
     
     
     
401. PESHOFF MM, Gupta P, Oberai S, Trivedi R, et al
     Triggering receptor expressed on myeloid cells 2 (TREM2) regulates phagocytosis in glioblastoma.
     Neuro Oncol. 2024 Jan 18:noad257. doi: 10.1093.
     PubMed     Abstract available
     
     
     
402. FLIES CM, Friedrich M, Lohmann P, van Garderen KA, et al
     Treatment-associated imaging changes in newly diagnosed MGMT promoter-methylated glioblastoma undergoing chemoradiation with or without cilengitide.
     Neuro Oncol. 2024 Jan 14:noad247. doi: 10.1093.
     PubMed     Abstract available
     
     
     
403. WEN PY, van den Bent M, Vogelbaum MA, Chang SM, et al
     RANO 2.0: The revised Response Assessment in Neuro-Oncology (RANO) criteria for high- and low-grade glial tumors in adults designed for the future.
     Neuro Oncol. 2024;26:2-4.
     PubMed    
     
     
     
404. DOHERTY C, Wilbanks B, Khatua S, Maher LJ 3rd, et al
     Aptamers in neuro-oncology: An emerging therapeutic modality.
     Neuro Oncol. 2024;26:38-54.
     PubMed     Abstract available
     
     
     
405. XING B, Lei Z, Wang Z, Wang Q, et al
     A disintegrin and metalloproteinase 22 activates integrin beta1 through its disintegrin domain to promote the progression of pituitary adenoma.
     Neuro Oncol. 2024;26:137-152.
     PubMed     Abstract available
     
     
     
406. BHUTADA I, Khambati F, Cheng SY, Tiek DM, et al
     CDK7 and CDK9 inhibition interferes with transcription, translation, and stemness, and induces cytotoxicity in GBM irrespective of temozolomide sensitivity.
     Neuro Oncol. 2024;26:70-84.
     PubMed     Abstract available
     
     
     
407. 
     Correction to: TSPO deficiency induces mitochondrial dysfunction, leading to hypoxia, angiogenesis, and a growth-promoting metabolic shift toward glycolysis in glioblastoma.
     Neuro Oncol. 2024 Jan 4:noad251. doi: 10.1093.
     PubMed    
     
     
     
408. ALBERT NL, Preusser M
     Measure what is measurable: PET RANO 1.0 criteria for interpretation of amino acid PET of diffuse gliomas.
     Neuro Oncol. 2024 Jan 2:noad228. doi: 10.1093.
     PubMed    
     
     
     
409. KARSCHNIA P, Dono A, Young JS, Juenger ST, et al
     Associations between recurrence patterns and outcome in glioblastoma patients undergoing re-resection: A complementary report of the RANO resect group.
     Neuro Oncol. 2024 Jan 2:noad237. doi: 10.1093.
     PubMed    
     
     
     December 2023
410. NEFF C, Price M, Cioffi G, Waite KA, et al
     The impact of the COVID-19 pandemic on treatment patterns in glioblastoma.
     Neuro Oncol. 2023 Dec 30:noad234. doi: 10.1093.
     PubMed    
     
     
     
411. LIU D, Zhu H, Cheng L, Li R, et al
     Hypoxia induced Galectin-8 maintains stemness in glioma stem cells via autophagy regulation.
     Neuro Oncol. 2023 Dec 30:noad264. doi: 10.1093.
     PubMed     Abstract available
     
     
     
412. FOLTYN-DUMITRU M, Kessler T, Sahm F, Wick W, et al
     Cluster-based prognostication in glioblastoma: Unveiling heterogeneity based on diffusion and perfusion similarities.
     Neuro Oncol. 2023 Dec 28:noad259. doi: 10.1093.
     PubMed     Abstract available
     
     
     
413. OBACZ J, Archambeau J, Lafont E, Nivet M, et al
     IRE1 endoribonuclease signaling promotes myeloid cell infiltration in glioblastoma.
     Neuro Oncol. 2023 Dec 28:noad256. doi: 10.1093.
     PubMed     Abstract available
     
     
     
414. RALEIGH DR
     Radiotherapy dose escalation for high-risk meningiomas after subtotal resection.
     Neuro Oncol. 2023 Dec 28:noad262. doi: 10.1093.
     PubMed    
     
     
     
415. MUELLER S, Fangusaro J, Thomas AO, Jacques TS, et al
     Consensus framework for conducting phase I/II clinical trials for children, adolescents, and young adults with pediatric low-grade glioma: Guidelines established by the International Pediatric Low-Grade Glioma Coalition Clinical Trial Working Group.
     Neuro Oncol. 2023 Dec 26:noad227. doi: 10.1093.
     PubMed     Abstract available
     
     
     
416. YAN S, Melnick K, He X, Lyu T, et al
     Developing a computable phenotype for glioblastoma.
     Neuro Oncol. 2023 Dec 23:noad249. doi: 10.1093.
     PubMed     Abstract available
     
     
     
417. DE SAUVAGE MA, Torrini C, Nieblas-Bedolla E, Summers E, et al
     The ERK inhibitor LY3214996 augments anti-PD-1 immunotherapy in preclinical mouse models of BRAFV600E melanoma brain metastasis.
     Neuro Oncol. 2023 Dec 22:noad248. doi: 10.1093.
     PubMed     Abstract available
     
     
     
418. MUELLER S, Kline C, Franson A, van der Lugt J, et al
     Rational combination platform trial design for children and young adults with Diffuse Midline Glioma: a report from PNOC.
     Neuro Oncol. 2023 Dec 20:noad181. doi: 10.1093.
     PubMed     Abstract available
     
     
     
419. 
     Correction to: Lessons learned from phase 3 trials of immunotherapy for glioblastoma: Time for longitudinal sampling?
     Neuro Oncol. 2023 Dec 18:noad241. doi: 10.1093.
     PubMed    
     
     
     
420. DUN MD, Odia Y, Arrillaga-Romany I
     Diffuse midline glioma, H3K27-altered: Illuminating the dark side of the moon.
     Neuro Oncol. 2023 Dec 18:noad245. doi: 10.1093.
     PubMed    
     
     
     
421. VAN DEN BENT M, Saratsis AM, Geurts M, Franceschi E, et al
     H3 K27M-altered Glioma and Diffuse Intrinsic Pontine Glioma: Semi-systematic Review of Treatment Landscape and Future Directions.
     Neuro Oncol. 2023 Dec 15:noad220. doi: 10.1093.
     PubMed     Abstract available
     
     
     
422. PATEL J, Aittaleb R, Doherty R, Gera A, et al
     Liquid Biopsy in H3K27M Diffuse Midline Glioma.
     Neuro Oncol. 2023 Dec 14:noad229. doi: 10.1093.
     PubMed     Abstract available
     
     
     
423. PUGAZENTHI S, Price M, De La Vega Gomar R, Kruchko C, et al
     Association of County-Level Socioeconomic Status with Meningioma Incidence and Outcomes.
     Neuro Oncol. 2023 Dec 13:noad223. doi: 10.1093.
     PubMed     Abstract available
     
     
     
424. KIM D, Ko HY, Chung JI, Park YM, et al
     Visualizing Cancer-Originating Acetate Uptake Through MCT1 in Reactive Astrocytes in the Glioblastoma Tumor Microenvironment.
     Neuro Oncol. 2023 Dec 12:noad243. doi: 10.1093.
     PubMed     Abstract available
     
     
     
425. DENG MY, Maas SLN, Hinz F, Karger CP, et al
     Efficacy and toxicity of bimodal radiotherapy in WHO grade 2 meningiomas following subtotal resection with carbon ion boost: prospective phase 2 MARCIE trial.
     Neuro Oncol. 2023 Dec 11:noad244. doi: 10.1093.
     PubMed     Abstract available
     
     
     
426. ALBERT NL, Furtner J, van den Bent MJ, Preusser M, et al
     The potential of amino acid PET imaging for prediction and monitoring of vorasidenib response in IDH-mutant gliomas.
     Neuro Oncol. 2023 Dec 9:noad240. doi: 10.1093.
     PubMed    
     
     
     
427. ZHANG J, Liu B, Xu C, Ji C, et al
     Cholesterol homeostasis confers glioma malignancy triggered by hnRNPA2B1-dependent regulation of SREBP2 and LDLR.
     Neuro Oncol. 2023 Dec 9:noad233. doi: 10.1093.
     PubMed     Abstract available
     
     
     
428. KIM AE, Lou KW, Giobbie-Hurder A, Chang K, et al
     Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance.
     Neuro Oncol. 2023 Dec 9:noad236. doi: 10.1093.
     PubMed     Abstract available
     
     
     
429. SUN Y, Mu G, Zhang X, Wu Y, et al
     Metabolic Modulation of Histone Acetylation Mediated by HMGCL Activates the FOXM1/beta-catenin Pathway in Glioblastoma.
     Neuro Oncol. 2023 Dec 9:noad232. doi: 10.1093.
     PubMed     Abstract available
     
     
     
430. NABORS B, Portnow J, Hattangadi-Gluth J, Horbinski C, et al
     NCCN CNS tumor guidelines update for 2023.
     Neuro Oncol. 2023;25:2114-2116.
     PubMed    
     
     
     
431. KARSCHNIA P, Arrillaga-Romany IC, Eichler A, Forst DA, et al
     Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells.
     Neuro Oncol. 2023;25:2239-2249.
     PubMed     Abstract available
     
     
     
432. BOELDERS SM, Gehring K, Postma EO, Rutten GJM, et al
     Cognitive functioning in untreated glioma patients: the limited predictive value of clinical variables.
     Neuro Oncol. 2023 Dec 1:noad221. doi: 10.1093.
     PubMed     Abstract available
     
     
     November 2023
433. XIN DE, Liao Y, Rao R, Ogurek S, et al
     Chaetocin-mediated SUV39H1 inhibition targets stemness and oncogenic networks of diffuse midline gliomas and synergizes with ONC201.
     Neuro Oncol. 2023 Nov 27:noad222. doi: 10.1093.
     PubMed     Abstract available
     
     
     
434. CHEN E, Ling AL, Reardon DA, Chiocca EA, et al
     Lessons learned from phase 3 trials of immunotherapy for glioblastoma: Time for longitudinal sampling?
     Neuro Oncol. 2023 Nov 23:noad211. doi: 10.1093.
     PubMed     Abstract available
     
     
     
435. RALEIGH DR, Preusser M
     A 34-gene expression biomarker predicts meningioma outcomes and radiotherapy responses.
     Neuro Oncol. 2023 Nov 15:noad212. doi: 10.1093.
     PubMed    
     
     
     
436. FANGUSARO J, Jones DT, Packer RJ, Gutmann DH, et al
     Pediatric low-grade glioma: State-of-the-art and ongoing challenges.
     Neuro Oncol. 2023 Nov 7:noad195. doi: 10.1093.
     PubMed     Abstract available
     
     
     
437. TURCAN S
     SIRT2 inhibition as the Achilles' heel of ATRX-deficient gliomas.
     Neuro Oncol. 2023 Nov 6:noad217. doi: 10.1093.
     PubMed    
     
     
     
438. LING AL, Chiocca EA
     Oncolytic immunoactivation associates with survival in a glioblastoma clinical trial.
     Neuro Oncol. 2023 Nov 6:noad216. doi: 10.1093.
     PubMed    
     
     
     
439. ZHENG J, Wang L, Zhao S, Zhang W, et al
     TREM2 mediates MHCII-associated CD4+ T cell response against gliomas.
     Neuro Oncol. 2023 Nov 6:noad214. doi: 10.1093.
     PubMed     Abstract available
     
     
     
440. DERBY S, Dutton L, Strathdee KE, Stevenson K, et al
     Inhibition of ATR opposes glioblastoma invasion through disruption of cytoskeletal networks and integrin internalisation via macropinocytosis.
     Neuro Oncol. 2023 Nov 4:noad210. doi: 10.1093.
     PubMed     Abstract available
     
     
     
441. DESISTO J, Donson AM, Griesinger AM, Fu R, et al
     Tumor and immune cell types interact to produce heterogeneous phenotypes of pediatric high grade glioma.
     Neuro Oncol. 2023 Nov 2:noad207. doi: 10.1093.
     PubMed     Abstract available
     
     
     
442. 
     Erratum to: EPIC-1042 as a potent PTRF/Cavin1-caveolin-1 interaction inhibitor to induce PARP1 autophagic degradation and suppress temozolomide efflux for glioblastoma.
     Neuro Oncol. 2023 Nov 1:noad200. doi: 10.1093.
     PubMed    
     
     
     October 2023
443. SIEBENGA FF, van der Weide HL, Gelmers F, Rakers SE, et al
     Emotion recognition in relation to tumor characteristics in patients with low-grade glioma.
     Neuro Oncol. 2023 Oct 31:noad209. doi: 10.1093.
     PubMed     Abstract available
     
     
     
444. HOTCHKISS KM, Cho E, Khasraw M
     A FIRST-IN-HUMAN PEPTIDE VACCINE TARGETING H3K27M; Encouraging Early Findings in Eight Adults with Diffuse Midline Glioma.
     Neuro Oncol. 2023 Oct 31:noad203. doi: 10.1093.
     PubMed    
     
     
     
445. COSENZA-CONTRERAS M, Schafer A, Sing J, Cook L, et al
     Proteometabolomics of initial and recurrent glioblastoma highlights an increased immune cell signature with altered lipid metabolism.
     Neuro Oncol. 2023 Oct 26:noad208. doi: 10.1093.
     PubMed     Abstract available
     
     
     
446. GERSHON R, Polevikov A, Karepov Y, Shenkar A, et al
     ;Frequencies of four Tumor-infiltrating lymphocytes potently predict survival in glioblastoma, an immune desert.
     Neuro Oncol. 2023 Oct 23:noad204. doi: 10.1093.
     PubMed     Abstract available
     
     
     
447. LEE JO, Ahn SS, Choi KS, Lee J, et al
     Added Prognostic Value of 3D Deep Learning-Derived Features from Preoperative MRI for Adult-type Diffuse Gliomas.
     Neuro Oncol. 2023 Oct 19:noad202. doi: 10.1093.
     PubMed     Abstract available
     
     
     
448. MCDONALD MF, Hossain A, Momin E, Hasan I, et al
     Tumor-specific Polycistronic miRNA Delivered by Engineered Exosomes for the Treatment of Glioblastoma.
     Neuro Oncol. 2023 Oct 17:noad199. doi: 10.1093.
     PubMed     Abstract available
     
     
     
449. ECKHARDT A, Drexler R, Schoof M, Struve N, et al
     Mean global DNA methylation serves as independent prognostic marker in IDH wild type glioblastoma.
     Neuro Oncol. 2023 Oct 11:noad197. doi: 10.1093.
     PubMed     Abstract available
     
     
     
450. SARATSIS AM, Knowles T, Petrovic A, Nazarian J, et al
     H3K27M Mutant Glioma: Disease Definition and Biological Underpinnings.
     Neuro Oncol. 2023 Oct 11:noad164. doi: 10.1093.
     PubMed     Abstract available
     
     
     
451. 
     Corrigendum to: Isocitrate dehydrogenase wt and IDHmut adult-type diffuse gliomas display distinct alterations in ribosome biogenesis and 2'O-methylation of ribosomal RNA.
     Neuro Oncol. 2023 Oct 10:noad192. doi: 10.1093.
     PubMed    
     
     
     
452. LOUGHAN AR, Lanoye A, Willis KD, Fox A, et al
     Telehealth group Cognitive Behavioral Therapy for Insomnia (CBT-I) in primary brain tumor: Primary outcomes from a single-arm Phase 2 feasibility and proof-of-concept trial.
     Neuro Oncol. 2023 Oct 5:noad193. doi: 10.1093.
     PubMed     Abstract available
     
     
     
453. OSTROM QT, Price M, Neff C, Cioffi G, et al
     CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016-2020.
     Neuro Oncol. 2023;25.
     PubMed     Abstract available
     
     
     
454. HANSFORD JR, Eisenstat DD
     No safe harbors for recurrent posterior fossa group A ependymoma: A time for change in risk assignment?
     Neuro Oncol. 2023;25:1868-1870.
     PubMed    
     
     
     
455. DONSON AM, Bertrand KC, Riemondy KA, Gao D, et al
     Significant increase of high-risk chromosome 1q gain and 6q loss at recurrence in posterior fossa group A ependymoma: A multicenter study.
     Neuro Oncol. 2023;25:1854-1867.
     PubMed     Abstract available
     
     
     September 2023
456. BOSKOVIC P, Wilke N, Man KH, Lichter P, et al
     BCAT1 regulates glioblastoma cell plasticity and contributes to immunosuppression.
     Neuro Oncol. 2023 Sep 28:noad190. doi: 10.1093.
     PubMed     Abstract available
     
     
     
457. KRESBACH C, Holst L, Schoof M, Leven T, et al
     Intraventricular SHH inhibition proves efficient in SHH medulloblastoma mouse model and prevents systemic side effects.
     Neuro Oncol. 2023 Sep 28:noad191. doi: 10.1093.
     PubMed     Abstract available
     
     
     
458. REMES TM, Suo-Palosaari MH, Arikoski PM, Harila M, et al
     Radiotherapy-induced vascular cognitive impairment 20 years after childhood brain tumor.
     Neuro Oncol. 2023 Sep 27:noad186. doi: 10.1093.
     PubMed     Abstract available
     
     
     
459. SAIJO A, Ogino H, Butowski NA, Tedesco MR, et al
     A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas.
     Neuro Oncol. 2023 Sep 27:noad185. doi: 10.1093.
     PubMed     Abstract available
     
     
     
460. 
     Correction to: Cancer-associated SMARCAL1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells.
     Neuro Oncol. 2023 Sep 26:noad180. doi: 10.1093.
     PubMed    
     
     
     
461. BIHN JR, Cioffi G, Waite KA, Kruchko C, et al
     Brain Tumors in United States Military Veterans.
     Neuro Oncol. 2023 Sep 22:noad182. doi: 10.1093.
     PubMed     Abstract available
     
     
     
462. ODDE D
     Glioblastoma Cell Invasion: Go? Grow? Yes.
     Neuro Oncol. 2023 Sep 22:noad178. doi: 10.1093.
     PubMed    
     
     
     
463. MILDE T, Fangusaro J, Fisher MJ, Hawkins C, et al
     Optimizing preclinical pediatric low-grade glioma models for meaningful clinical translation.
     Neuro Oncol. 2023 Sep 21:noad125. doi: 10.1093.
     PubMed     Abstract available
     
     
     
464. DESHPANDE K, Martirosian V, Nakamura BN, Das D, et al
     SRRM4-mediated REST to REST4 dysregulation promotes tumor growth and neural adaptation in breast cancer leading to brain metastasis.
     Neuro Oncol. 2023 Sep 16:noad175. doi: 10.1093.
     PubMed     Abstract available
     
     
     
465. KRAMER C, Kilian M, Chih YC, Kourtesakis A, et al
     NLGN4X TCR transgenic T cells to treat gliomas.
     Neuro Oncol. 2023 Sep 16:noad172. doi: 10.1093.
     PubMed     Abstract available
     
     
     
466. JOHNSON TS, MacDonald TJ, Pacholczyk R, Aguilera D, et al
     Indoximod-based chemo-immunotherapy for pediatric brain tumors: a first-in-children phase 1 trial.
     Neuro Oncol. 2023 Sep 16:noad174. doi: 10.1093.
     PubMed     Abstract available
     
     
     
467. TOBOCHNIK S, Dorotan MKC, Ghosh HS, Lapinskas E, et al
     Glioma genetic profiles associated with electrophysiologic hyperexcitability.
     Neuro Oncol. 2023 Sep 15:noad176. doi: 10.1093.
     PubMed     Abstract available
     
     
     
468. MISHRA DK, Popovski D, Morris SM, Bondoc A, et al
     Preclinical Pediatric Brain Tumor Models for Immunotherapy: Hurdles and a Way Forward.
     Neuro Oncol. 2023 Sep 15:noad170. doi: 10.1093.
     PubMed     Abstract available
     
     
     
469. 
     Correction to: HGG-16. COMPARATIVE ANALYSIS OF AUTOPHAGY IN DRUG RESPONSES AND AGGRESSIVE BEHAVIOR OF ADULT VERSUS PEDIATRIC GLIOMA CELL LINES.
     Neuro Oncol. 2023 Sep 13:noad168. doi: 10.1093.
     PubMed    
     
     
     
470. BRUSCHI M, Midjek L, Ajlil Y, Vairy S, et al
     Diffuse Midline Glioma Invasion and Metastasis Rely on Cell-autonomous Signaling.
     Neuro Oncol. 2023 Sep 13:noad161. doi: 10.1093.
     PubMed     Abstract available
     
     
     
471. 
     Correction to: Mapping pediatric brain tumors to their origins in the developing cerebellum.
     Neuro Oncol. 2023 Sep 12:noad167. doi: 10.1093.
     PubMed    
     
     
     
472. AVILA EK, Tobochnik S, Inati SK, Koekkoek JAF, et al
     Brain tumor-related epilepsy management: A Society for Neuro-oncology (SNO) consensus review on current management.
     Neuro Oncol. 2023 Sep 12:noad154. doi: 10.1093.
     PubMed     Abstract available
     
     
     
473. SHI DD, Kaelin WG
     The INDIGO Trial: Precision Medicine Finally Comes to Glioma.
     Neuro Oncol. 2023 Sep 12:noad162. doi: 10.1093.
     PubMed    
     
     
     
474. CAHILL DP, Dunn GP
     Considering the Extent of Resection in Diffuse Glioma.
     Neuro Oncol. 2023 Sep 7:noad165. doi: 10.1093.
     PubMed    
     
     
     
475. BROWN AL, Sok P, Raghubar KP, Lupo PJ, et al
     Genetic susceptibility to cognitive decline following craniospinal irradiation for pediatric central nervous system tumors.
     Neuro Oncol. 2023;25:1698-1708.
     PubMed     Abstract available
     
     
     
476. CHARBONNEAU M, Harper K, Brochu-Gaudreau K, Perreault A, et al
     The development of a rapid patient-derived xenograft model to predict chemotherapeutic drug sensitivity/resistance in malignant glial tumors.
     Neuro Oncol. 2023;25:1605-1616.
     PubMed     Abstract available
     
     
     
477. KARSCHNIA P, Dietrich J, Bruno F, Dono A, et al
     Surgical management and outcome of newly diagnosed glioblastoma without contrast enhancement ('low grade appearance') - a report of the RANO resect group.
     Neuro Oncol. 2023 Sep 4:noad160. doi: 10.1093.
     PubMed     Abstract available
     
     
     August 2023
478. HONG B, Yang E, Su D, Ju J, et al
     EPIC-1042 as a potent PTRF/Cavin1-Caveolin-1 interaction inhibitor to induce PARP1 autophagic degradation and suppress temozolomide efflux for Glioblastoma.
     Neuro Oncol. 2023 Aug 31:noad159. doi: 10.1093.
     PubMed     Abstract available
     
     
     
479. PINSON H, Silversmit G, Vanhauwaert D, Vanschoenbeek K, et al
     Epidemiology and survival of adult-type diffuse glioma in Belgium during the molecular era.
     Neuro Oncol. 2023 Aug 31:noad158. doi: 10.1093.
     PubMed     Abstract available
     
     
     
480. MALGULWAR PB, Danussi C, Dharmaiah S, Johnson W, et al
     Sirtuin 2 inhibition modulates chromatin landscapes genome-wide to induce senescence in ATRX-deficient malignant glioma.
     Neuro Oncol. 2023 Aug 25:noad155. doi: 10.1093.
     PubMed     Abstract available
     
     
     
481. GU D, You H, Gao J, You Y, et al
     Reply to "Targeting cholesterol homeostasis through inhibiting: An Achilles' heel for glioblastoma?".
     Neuro Oncol. 2023 Aug 25:noad146. doi: 10.1093.
     PubMed    
     
     
     
482. SUN Y, Mu G, Xue Z, Wang S, et al
     Targeting cholesterol homeostasis through inhibiting SREBP-2: An Achilles' heel for glioblastoma.
     Neuro Oncol. 2023 Aug 25:noad145. doi: 10.1093.
     PubMed    
     
     
     
483. HUANG W, Li J, Zhu H, Qin X, et al
     A novel EGFR variant EGFRx maintains glioblastoma stem cells through STAT5.
     Neuro Oncol. 2023 Aug 24:noad153. doi: 10.1093.
     PubMed     Abstract available
     
     
     
484. KAN P, Srinivasan VM, Gumin J, Garcia R, et al
     Development of a Rabbit Human Glioblastoma Model for Testing of Endovascular Selective Intra-Arterial Infusion (ESIA) of Novel Stem Cell-Based Therapeutics.
     Neuro Oncol. 2023 Aug 21:noad152. doi: 10.1093.
     PubMed     Abstract available
     
     
     
485. PATEL KS, Yao J, Cho NS, Sanvito F, et al
     pH-Weighted Amine Chemical Exchange Saturation Transfer Echo Planar Imaging (CEST-EPI) Visualizes Infiltrating Glioblastoma Cells.
     Neuro Oncol. 2023 Aug 18:noad150. doi: 10.1093.
     PubMed     Abstract available
     
     
     
486. FRANCIS SS, Guerra G, Hansen HM, Wendt G, et al
     Inherited polymorphisms in the Human Leukocyte Antigen Region modify the association between varicella-zoster virus antibody reactivity and glioma prognosis.
     Neuro Oncol. 2023 Aug 18:noad122. doi: 10.1093.
     PubMed    
     
     
     
487. GALLO M
     Prognostic value of integrative genomic approaches for IDH-mutant gliomas.
     Neuro Oncol. 2023 Aug 17:noad151. doi: 10.1093.
     PubMed    
     
     
     
488. JACKSON ER, Persson ML, Fish CJ, Findlay IJ, et al
     A review of the anti-tumor potential of current therapeutics targeting the mitochondrial protease ClpP in H3K27-altered, diffuse midline glioma.
     Neuro Oncol. 2023 Aug 17:noad144. doi: 10.1093.
     PubMed     Abstract available
     
     
     
489. SHENOY G, Connor JR
     A Closer Look at the Role of Iron in Glioblastoma.
     Neuro Oncol. 2023 Aug 4:noad136. doi: 10.1093.
     PubMed     Abstract available
     
     
     
490. OKONECHNIKOV K, Joshi P, Sepp M, Leiss K, et al
     Mapping pediatric brain tumors to their origins in the developing cerebellum.
     Neuro Oncol. 2023 Aug 3:noad124. doi: 10.1093.
     PubMed     Abstract available
     
     
     
491. ROBERTS KF, Dahiya SM
     Mitotic index is (still) important for grading isocitrate dehydrogenase (IDH)-mutant astrocytoma.
     Neuro Oncol. 2023;25:1450-1451.
     PubMed    
     
     
     
492. FENG J, Duan Z, Yao K, Gui Q, et al
     Primary papillary epithelial tumor of the sella and posterior pituitary tumor show similar (epi)genetic features and constitute a single neuro-oncological entity.
     Neuro Oncol. 2023;25:1487-1497.
     PubMed     Abstract available
     
     
     
493. KOJIC M, Maybury MK, Waddell N, Koufariotis LT, et al
     Efficient detection and monitoring of pediatric brain malignancies with liquid biopsy based on patient-specific somatic mutation screening.
     Neuro Oncol. 2023;25:1507-1517.
     PubMed     Abstract available
     
     
     
494. KROS JM, Rushing E, Uwimana AL, Hernandez-Lain A, et al
     Mitotic count is prognostic in IDH mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trial 26053 (CATNON) and EORTC trial 22033-26033.
     Neuro Oncol. 2023;25:1443-1449.
     PubMed     Abstract available
     
     
     
495. ZUCCATO JA, Patil V, Mansouri S, Voisin M, et al
     Cerebrospinal fluid methylome-based liquid biopsies for accurate malignant brain neoplasm classification.
     Neuro Oncol. 2023;25:1452-1460.
     PubMed     Abstract available
     
     
     
496. PARAQINDES H, Mourksi NE, Ballesta S, Hedjam J, et al
     IDHwt and IDHmut adult-type diffuse gliomas display distinct alterations in ribosome biogenesis and 2'O-methylation of ribosomal RNA.
     Neuro Oncol. 2023 Aug 2:noad140. doi: 10.1093.
     PubMed     Abstract available
     
     
     
497. APFELBAUM A, Bandopadhayay P
     The 'LOGGIC' of RNA-sequencing in enhancing diagnoses of pediatric low-grade gliomas.
     Neuro Oncol. 2023 Aug 2:noad142. doi: 10.1093.
     PubMed    
     
     
     
498. 
     Corrigendum to: USP36 promotes tumorigenesis and drug sensitivity of glioblastoma by deubiquitinating and stabilizing ALKBH5.
     Neuro Oncol. 2023 Aug 1:noad135. doi: 10.1093.
     PubMed    
     
     
     
499. MONJE M, Cooney T, Glod J, Huang J, et al
     A Phase I Trial of Panobinostat in Children with Diffuse Intrinsic Pontine Glioma: A Report from the Pediatric Brain Tumor Consortium (PBTC-047).
     Neuro Oncol. 2023 Aug 1:noad141. doi: 10.1093.
     PubMed     Abstract available
     
     
     July 2023
500. ROTH P
     CARs in the brain: can we tackle glioblastoma with engineered NK cells?
     Neuro Oncol. 2023 Jul 31:noad131. doi: 10.1093.
     PubMed    
     
     
     
501. CHIANG J, Bagchi A, Li X, Dhanda SK, et al
     High-grade glioma in infants and young children is histologically, molecularly, and clinically diverse-Results from the SJYC07 trial and institutional experience.
     Neuro Oncol. 2023 Jul 28:noad130. doi: 10.1093.
     PubMed     Abstract available
     
     
     
502. YOUNG JS, Morshed RA, Hervey-Jumper SL, Berger MS, et al
     The Surgical Management of Diffuse Gliomas: Current State of Neurosurgical Management and Future Directions.
     Neuro Oncol. 2023 Jul 27:noad133. doi: 10.1093.
     PubMed     Abstract available
     
     
     
503. LIU RZ, Choi WS, Jain S, Xu X, et al
     Stationary-to-migratory transition in glioblastoma stem-like cells driven by a FABP7-RXRalpha neurogenic pathway.
     Neuro Oncol. 2023 Jul 27:noad134. doi: 10.1093.
     PubMed     Abstract available
     
     
     
504. WOLIN AR, Vincent MY, Hotz T, Purdy SC, et al
     EYA2 Tyrosine Phosphatase Inhibition Reduces MYC and Prevents Medulloblastoma Progression.
     Neuro Oncol. 2023 Jul 24:noad128. doi: 10.1093.
     PubMed     Abstract available
     
     
     
505. HALL MD, Kotecha R
     Social Determinants of Health: A Forgotten Risk Factor for Neurocognition in Pediatric Brain Tumor Survivors.
     Neuro Oncol. 2023 Jul 24:noad127. doi: 10.1093.
     PubMed    
     
     
     
506. PREUSSER M, Geurts M, Hainfellner JA, van den Bent MJ, et al
     What is an isocitrate dehydrogenase-mutated central nervous system World Health Organization grade 2 glioma, or who should receive vorasidenib?
     Neuro Oncol. 2023 Jul 21:noad113. doi: 10.1093.
     PubMed    
     
     
     
507. MAMATJAN Y, Voisin M, Nassiri F, Moraes FY, et al
     Integrated molecular analysis reveals hypermethylation and overexpression of HOX genes to be poor prognosticators in IDH mutant glioma.
     Neuro Oncol. 2023 Jul 20:noad126. doi: 10.1093.
     PubMed     Abstract available
     
     
     
508. HOU J, Huang P, Xu M, Wang H, et al
     NCAPG promotes the progression of glioblastoma by facilitating PARP1-mediated E2F1 transactivation.
     Neuro Oncol. 2023 Jul 9:noad111. doi: 10.1093.
     PubMed     Abstract available
     
     
     
509. LAPRIE A, Noel G, Chaltiel L, Truc G, et al
     Randomized phase III trial of metabolic imaging-guided dose escalation of radio-chemotherapy in patients with newly diagnosed glioblastoma (SPECTRO GLIO trial).
     Neuro Oncol. 2023 Jul 7:noad119. doi: 10.1093.
     PubMed     Abstract available
     
     
     
510. CHANG SM
     Increasing growth and impact of Neuro-Oncology.
     Neuro Oncol. 2023;25:1199.
     PubMed    
     
     
     
511. 
     Erratum to: METB-13. A SINGLE-CELL GENETIC IN VIVO LINEAGE-TRACING PLATFORM FOR MEDULLOBLASTOMA.
     Neuro Oncol. 2023 Jul 6:noad116. doi: 10.1093.
     PubMed    
     
     
     
512. POON MTC, Piper RJ, Thango N, Fountain DM, et al
     Variation in postoperative outcomes of patients with intracranial tumors: insights from a prospective international cohort study during the COVID-19 pandemic.
     Neuro Oncol. 2023;25:1299-1309.
     PubMed     Abstract available
     
     
     
513. WELLER M, Le Rhun E, Van den Bent M, Chang SM, et al
     Diagnosis and management of complications from the treatment of primary central nervous system tumors in adults.
     Neuro Oncol. 2023;25:1200-1224.
     PubMed     Abstract available
     
     
     
514. TRAGER M, Schweizer L, Perez E, Schmid S, et al
     Adult intracranial ependymoma-relevance of DNA methylation profiling for diagnosis, prognosis, and treatment.
     Neuro Oncol. 2023;25:1286-1298.
     PubMed     Abstract available
     
     
     
515. RAMMOHAN N, Ho A, Besson P, Kruser TJ, et al
     Whole-brain radiotherapy associated with structural changes resembling aging as determined by anatomic surface-based deep learning.
     Neuro Oncol. 2023;25:1323-1330.
     PubMed     Abstract available
     
     
     
516. SMOLL NR, Brady Z, Scurrah KJ, Lee C, et al
     Computed tomography scan radiation and brain cancer incidence.
     Neuro Oncol. 2023;25:1368-1376.
     PubMed     Abstract available
     
     
     
517. NOCH EK, Palma LN, Yim I, Bullen N, et al
     Insulin feedback is a targetable resistance mechanism of PI3K inhibition in glioblastoma.
     Neuro Oncol. 2023 Jul 3:noad117. doi: 10.1093.
     PubMed     Abstract available
     
     
     June 2023
518. VAN SCHAIK J, Schouten-van Meeteren AYN, Vos-Kerkhof E, Janssens GO, et al
     Treatment and outcome of the Dutch Childhood Craniopharyngioma Cohort study; first results after centralization of care.
     Neuro Oncol. 2023 Jun 29:noad112. doi: 10.1093.
     PubMed     Abstract available
     
     
     
519. ZHAO Y, Gu S, Li L, Zhao R, et al
     A novel risk signature for predicting brain metastasis in patients with lung adenocarcinoma.
     Neuro Oncol. 2023 Jun 28:noad115. doi: 10.1093.
     PubMed     Abstract available
     
     
     
520. KOLODZIEJCZAK AS, Guerrini-Rousseau L, Planchon JM, Ecker J, et al
     Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome.
     Neuro Oncol. 2023 Jun 28:noad114. doi: 10.1093.
     PubMed     Abstract available
     
     
     
521. HANSCH L, Peipp M, Mastall M, Villars D, et al
     Chimeric antigen receptor (CAR) T cell-based targeting of CD317 as a novel immunotherapeutic strategy against glioblastoma.
     Neuro Oncol. 2023 Jun 19:noad108. doi: 10.1093.
     PubMed     Abstract available
     
     
     
522. RATLIFF M, Karimian-Jazi K, Hoffmann DC, Rauschenbach L, et al
     Individual glioblastoma cells harbor both proliferative and invasive capabilities during tumor progression.
     Neuro Oncol. 2023 Jun 19:noad109. doi: 10.1093.
     PubMed     Abstract available
     
     
     
523. KOCAKAVUK E, Johnson KC, Sabedot TS, Reinhardt HC, et al
     Hemizygous CDKN2A deletion confers worse survival outcomes in IDHmut-noncodel gliomas.
     Neuro Oncol. 2023 Jun 17:noad095. doi: 10.1093.
     PubMed    
     
     
     
524. CHAN P, Rich JN, Kay SA
     Watching the Clock in Glioblastoma.
     Neuro Oncol. 2023 Jun 16:noad107. doi: 10.1093.
     PubMed     Abstract available
     
     
     
525. MUELLER S, Kline C, Stoller S, Lundy S, et al
     PNOC015: Repeated convection enhanced delivery (CED) of MTX110 (aqueous panobinostat) in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG).
     Neuro Oncol. 2023 Jun 15:noad105. doi: 10.1093.
     PubMed     Abstract available
     
     
     
526. HOTCHKISS KM, Batich KA, Mohan A, Rahman R, et al
     Dendritic cell vaccine trials in gliomas: Untangling the lines.
     Neuro Oncol. 2023 Jun 8:noad088. doi: 10.1093.
     PubMed     Abstract available
     
     
     
527. KULIESIUTE U, Joseph K, Straehle J, Ravi VM, et al
     Sialic acid metabolism orchestrates transcellular connectivity and signalling in glioblastoma.
     Neuro Oncol. 2023 Jun 8:noad101. doi: 10.1093.
     PubMed     Abstract available
     
     
     
528. HUANG N, Chen Z, Yang X, Gao Y, et al
     Upstream Open Reading Frame-encoded MP31 Disrupts the Mitochondrial Quality Control Process and Inhibits Tumorigenesis in Glioblastoma.
     Neuro Oncol. 2023 Jun 6:noad099. doi: 10.1093.
     PubMed     Abstract available
     
     
     
529. XIN L, Tan Y, Zhu Y, Cui X, et al
     EPIC-0307-mediated selective disruption of PRADX-EZH2 interaction and enhancement of temozolomide sensitivity to glioblastoma via inhibiting DNA repair and MGMT.
     Neuro Oncol. 2023 Jun 5:noad102. doi: 10.1093.
     PubMed     Abstract available
     
     
     
530. BAILLEUL J, Ruan Y, Abdulrahman L, Scott AJ, et al
     PKM2 rewires glucose metabolism during radiation therapy to promote an antioxidant response and glioblastoma radioresistance.
     Neuro Oncol. 2023 Jun 5:noad103. doi: 10.1093.
     PubMed     Abstract available
     
     
     
531. SAHM F, Brandner S, Bertero L, Capper D, et al
     Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline.
     Neuro Oncol. 2023 Jun 2:noad100. doi: 10.1093.
     PubMed     Abstract available
     
     
     
532. ALI UM, Withrow DR, Judge AD, Plaha P, et al
     Temporal trends in the incidence of malignant and nonmalignant primary brain and central nervous system tumors by the method of diagnosis in England, 1993-2017.
     Neuro Oncol. 2023;25:1177-1192.
     PubMed     Abstract available
     
     
     
533. SUN T, Wang Y, Liu X, Li Z, et al
     Deep learning based on preoperative magnetic resonance (MR) images improves the predictive power of survival models in primary spinal cord astrocytomas.
     Neuro Oncol. 2023;25:1157-1165.
     PubMed     Abstract available
     
     
     
534. ZAYTSEVA M, Valiakhmetova A, Yasko L, Samarin A, et al
     Molecular heterogeneity of pediatric choroid plexus carcinomas determines the distinctions in clinical course and prognosis.
     Neuro Oncol. 2023;25:1132-1145.
     PubMed     Abstract available
     
     
     
535. DEMIRDIZEN E, Al-Ali R, Narayanan A, Sun X, et al
     TRIM67 drives tumorigenesis in oligodendrogliomas through Rho GTPase-dependent membrane blebbing.
     Neuro Oncol. 2023;25:1031-1043.
     PubMed     Abstract available
     
     
     
536. LAMBA N, Cagney DN, Catalano PJ, Kim D, et al
     A Genomic Score to Predict Local Control among Patients with Brain Metastases Managed with Radiation.
     Neuro Oncol. 2023 Jun 1:noad098. doi: 10.1093.
     PubMed     Abstract available
     
     
     May 2023
537. KARSCHNIA P, Dono A, Young JS, Juenger ST, et al
     Prognostic evaluation of re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: A report of the RANO resect group.
     Neuro Oncol. 2023 May 30:noad074. doi: 10.1093.
     PubMed     Abstract available
     
     
     
538. 
     Correction to: Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma.
     Neuro Oncol. 2023 May 29:noad091. doi: 10.1093.
     PubMed    
     
     
     
539. 
     Corrigendum to: Identifying risk factors for recurrence/relapse in NF1 optic pathway gliomas: Moving forward by looking back.
     Neuro Oncol. 2023 May 25:noad093. doi: 10.1093.
     PubMed    
     
     
     
540. 
     Correction to: Progress for patients with melanoma brain metastases.
     Neuro Oncol. 2023 May 19:noad089. doi: 10.1093.
     PubMed    
     
     
     
541. 
     Corrigendum to: Clinical, histological, and molecular features of gliomas in adults with neurofibromatosis type 1.
     Neuro Oncol. 2023 May 19:noad094. doi: 10.1093.
     PubMed    
     
     
     
542. NEHAMA D, Woodell AS, Maingi SM, Hingtgen SD, et al
     Cell-based therapies for glioblastoma: Promising tools against tumor heterogeneity.
     Neuro Oncol. 2023 May 14:noad092. doi: 10.1093.
     PubMed     Abstract available
     
     
     
543. 
     Retraction of: PTEN loss drives resistance to the neddylation inhibitor MLN4924 in glioblastoma and can be overcome with TOP2A inhibitors.
     Neuro Oncol. 2023 May 13:noad081. doi: 10.1093.
     PubMed    
     
     
     
544. HAASE S, Lowenstein PR, Castro MG
     "Sabotaging the Protein Factory to Overcome Glioma Stem Cell Resistance".
     Neuro Oncol. 2023 May 13:noad090. doi: 10.1093.
     PubMed    
     
     
     
545. DI NUNNO V, Gatto L, Tosoni A, Bartolini S, et al
     Letter concerning "Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between ORR and median overall survival": Toward surrogate endpoints for phase II trials in patients with recurrent gliobla
     Neuro Oncol. 2023 May 12:noad071. doi: 10.1093.
     PubMed    
     
     
     
546. ELLINGSON BM, Wen PY, Cloughesy TF
     Reply to Di Nunno et al. concerning objective response rates targets for recurrent glioblastoma clinical trials: Toward surrogate endpoints for phase II trials in patients with recurrent glioblastoma.
     Neuro Oncol. 2023 May 11:noad085. doi: 10.1093.
     PubMed    
     
     
     
547. BURGER MC, Forster MT, Romanski A, Strassheimer F, et al
     Intracranial injection of NK cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma.
     Neuro Oncol. 2023 May 6:noad087. doi: 10.1093.
     PubMed     Abstract available
     
     
     
548. LAMBA N, Cagney DN, Catalano PJ, Elhalawani H, et al
     Incidence proportion and prognosis of leptomeningeal disease among patients with breast vs. non-breast primaries.
     Neuro Oncol. 2023;25:973-983.
     PubMed     Abstract available
     
     
     
549. ALLEN BD, Alaghband Y, Kramar EA, Ru N, et al
     Elucidating the neurological mechanism of the FLASH effect in juvenile mice exposed to hypofractionated radiotherapy.
     Neuro Oncol. 2023;25:927-939.
     PubMed     Abstract available
     
     
     
550. HUANG J, Chan SC, Lok V, Zhang L, et al
     Disease burden, risk factors, and trends of primary central nervous system (CNS) cancer: A global study of registries data.
     Neuro Oncol. 2023;25:995-1005.
     PubMed     Abstract available
     
     
     April 2023
551. JO J, Diaz M, Horbinski C, Mackman N, et al
     Epidemiology, biology, and management of venous thromboembolism in gliomas: An interdisciplinary review.
     Neuro Oncol. 2023 Apr 26:noad059. doi: 10.1093.
     PubMed     Abstract available
     
     
     
552. MULE' TN, Hodges J, Wu S, Li Y, et al
     Social Determinants of Cognitive Outcomes in Survivors of Pediatric Brain Tumors Treated with Conformal Radiation Therapy.
     Neuro Oncol. 2023 Apr 26:noad080. doi: 10.1093.
     PubMed     Abstract available
     
     
     
553. KOEKKOEK JAF, van der Meer PB, Walbert T
     Reply to the letter regarding "Palliative care and end-of-life care in adults with malignant brain tumors".
     Neuro Oncol. 2023 Apr 25:noad069. doi: 10.1093.
     PubMed    
     
     
     
554. LIU G, Zhang P, Chen S, Chen Z, et al
     FAM129A promotes self-renewal and maintains invasive status via stabilizing the Notch intracellular domain in glioma stem cells.
     Neuro Oncol. 2023 Apr 21:noad079. doi: 10.1093.
     PubMed     Abstract available
     
     
     
555. MILLER AM, Karajannis MA
     Cerebrospinal fluid: the new frontier for methylome-based diagnostic classification of brain tumors.
     Neuro Oncol. 2023 Apr 20:noad075. doi: 10.1093.
     PubMed    
     
     
     
556. HARDIN EC, Schmid S, Sommerkamp A, Bodden C, et al
     LOGGIC Core BioClinical Data Bank: Added clinical value of RNA-Seq in an international molecular diagnostic registry for pediatric low-grade glioma patients.
     Neuro Oncol. 2023 Apr 19:noad078. doi: 10.1093.
     PubMed     Abstract available
     
     
     
557. BARBIERI F, Bajetto A, Dellacasagrande I, Solari A, et al
     Stem-like signatures in human meningioma cells are under the control of CXCL11/CXCL12 chemokine activity.
     Neuro Oncol. 2023 Apr 19:noad076. doi: 10.1093.
     PubMed     Abstract available
     
     
     
558. CONTRERAS-ZARATE MJ, Alvarez-Eraso KLF, Jaramillo-Gomez JA, Littrell Z, et al
     Short-term topiramate treatment prevents radiation-induced cytotoxic edema in preclinical models of breast-cancer brain metastasis.
     Neuro Oncol. 2023 Apr 13:noad070. doi: 10.1093.
     PubMed     Abstract available
     
     
     
559. MISHIMA K, Nishikawa R, Narita Y, Mizusawa J, et al
     Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C.
     Neuro Oncol. 2023;25:687-698.
     PubMed     Abstract available
     
     
     
560. LI X, Moreira DC, Bag AK, Qaddoumi I, et al
     The clinical and molecular characteristics of progressive hypothalamic/optic pathway pilocytic astrocytoma.
     Neuro Oncol. 2023;25:750-760.
     PubMed     Abstract available
     
     
     
561. FU R, Norris GA, Willard N, Griesinger AM, et al
     Spatial transcriptomic analysis delineates epithelial and mesenchymal subpopulations and transition stages in childhood ependymoma.
     Neuro Oncol. 2023;25:786-798.
     PubMed     Abstract available
     
     
     
562. SELT F, Sigaud R, Valinciute G, Sievers P, et al
     BH3 mimetics targeting BCL-XL impact the senescent compartment of pilocytic astrocytoma.
     Neuro Oncol. 2023;25:735-747.
     PubMed     Abstract available
     
     
     
563. STOLTZE UK, Foss-Skiftesvik J, van Overeem Hansen T, Byrjalsen A, et al
     Genetic predisposition and evolutionary traces of pediatric cancer risk: a prospective 5-year population-based genome sequencing study of children with CNS tumors.
     Neuro Oncol. 2023;25:761-773.
     PubMed     Abstract available
     
     
     
564. 
     Corrigendum to: NCOG-45. DIFFERENTIAL AND DOSE-DEPENDENT EFFECTS OF CRANIAL IRRADIATION ON BRAIN STRUCTURES AND NEUROPSYCHOLOGICAL OUTCOMES IN CHILDREN WITH POSTERIOR FOSSA BRAIN TUMORS TREATED WITH DIFFERENT MODALITIES.
     Neuro Oncol. 2023 Apr 1:noad058. doi: 10.1093.
     PubMed    
     
     
     March 2023
565. 
     Corrigendum to: Association of circulating markers with cognitive decline after radiation therapy for brain metastasis.
     Neuro Oncol. 2023 Mar 29:noad062. doi: 10.1093.
     PubMed    
     
     
     
566. GOENKA A, Song X, Tiek D, Iglesia RP, et al
     Oncogenic Long Non-coding RNA LINC02283 Enhances PDGF Receptor A mediated Signaling and Drives Glioblastoma Tumorigenesis.
     Neuro Oncol. 2023 Mar 29:noad065. doi: 10.1093.
     PubMed     Abstract available
     
     
     
567. XIE J, Kuriakose T, Bianski B, Twarog N, et al
     ATM inhibition enhances the efficacy of radiation across distinct molecular subgroups of pediatric high-grade glioma.
     Neuro Oncol. 2023 Mar 27:noad064. doi: 10.1093.
     PubMed     Abstract available
     
     
     
568. WERNER JM, Wollring MM, Tscherpel C, Rosen EK, et al
     Multimodal imaging findings in patients with glioblastoma with extensive coagulative necrosis related to regorafenib.
     Neuro Oncol. 2023 Mar 24:noad051. doi: 10.1093.
     PubMed    
     
     
     
569. 
     Corrigendum to: IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification.
     Neuro Oncol. 2023 Mar 21:noad048. doi: 10.1093.
     PubMed    
     
     
     
570. GU D, Zhou F, You H, Gao J, et al
     SREBP2 maintains glioblastoma stem cells through keeping the balance between cholesterol biosynthesis and uptake.
     Neuro Oncol. 2023 Mar 19:noad060. doi: 10.1093.
     PubMed     Abstract available
     
     
     
571. BAUCHET L, Sanson M
     Deciphering gliomagenesis from GWAS.
     Neuro Oncol. 2023 Mar 14:noad057. doi: 10.1093.
     PubMed    
     
     
     
572. KUMTHEKAR PU, Avram MJ, Lassman AB, Lin NU, et al
     A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics.
     Neuro Oncol. 2023;25:557-565.
     PubMed     Abstract available
     
     
     
573. VOLLMUTH P, Foltyn M, Huang RY, Galldiks N, et al
     Artificial intelligence (AI)-based decision support improves reproducibility of tumor response assessment in neuro-oncology: An international multi-reader study.
     Neuro Oncol. 2023;25:533-543.
     PubMed     Abstract available
     
     
     
574. SPERDUTO PW, Salama AKS, Anders C
     Progress for Patients with Melanoma Brain Metastases.
     Neuro Oncol. 2023 Mar 8:noad050. doi: 10.1093.
     PubMed    
     
     
     
575. GROSSMAN SA
     Using Historical Objective Response Rates to Design Single Arm Phase II Trials in Patients with Recurrent Glioblastoma.
     Neuro Oncol. 2023 Mar 7:noad046. doi: 10.1093.
     PubMed    
     
     
     
576. YANG Y, Brown MC, Zhang G, Stevenson K, et al
     Polio Virotherapy Targets the Malignant Glioma Myeloid Infiltrate with Diffuse Microglia Activation Engulfing the CNS.
     Neuro Oncol. 2023 Mar 2:noad052. doi: 10.1093.
     PubMed     Abstract available
     
     
     
577. DREXLER R, Gottsche J, Sauvigny T, Schuller U, et al
     Targeted anticonvulsive treatment of IDH-wildtype glioblastoma based on DNA methylation subclasses.
     Neuro Oncol. 2023 Mar 1:noad014. doi: 10.1093.
     PubMed    
     
     
     February 2023
578. ROMO CG, Piotrowski AF, Campian JL, Diarte J, et al
     Clinical, Histological and Molecular Features of Gliomas in Adults with Neurofibromatosis Type 1.
     Neuro Oncol. 2023 Feb 25:noad033. doi: 10.1093.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Neoplasms of the CNS is free of charge.